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As the international poultry industry searches for antibiotic alternatives, dietary
probiotic supplementation has exhibited the ability to decrease FCR, increase live weight
gain, and regulate inflammatory responses within the gut of broiler chickens. The in ovo
(or in egg) supplementation of probiotics has the potential for promoting early
colonization of probiotic bacteria in the gastrointestinal tract and providing enhanced
protection against pathogens in the hatchery and grow-out facilities. In the present
studies, the in ovo injection of either L. animalis + E. faecium combination or L. animalis
+ B. licheniformis combination on d 18 of incubation does not negatively affect the
chick’s ability to hatch out of the egg. These combinations also influence post-hatch
performance, where FCR, gastrointestinal tissue weights, and immune-physiological
parameters were impacted under non-challenged and coccidiosis-challenged grow-out
conditions. These results indicate the physiological and immunomodulatory role that
beneficial bacteria may have on a developing chick.
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INTRODUCTION
Through the application of subtherapeutic dosages of antibiotics in feed, the
poultry industry has managed to maintain highly efficient bird performance at a low cost
since the early 1950s (Hill and Branion, 1950; Vermeulen et al., 2002). With this
production practice, there is an increasing concern for the development of antibiotic
resistant bacteria (Fuller, 1989). Antibiotic resistant bacteria species have led to food
safety and human health concerns since these pathogenic bacteria species are commonly
found in livestock animals and soil (Pires et al., 2009). Recently, the CDC (2017)
observed that chicken products were one of the most common sources of foodborne
illness in the United States, accounting for over 10% of all foodborne disease outbreaks
and associated illnesses annually. Concurrently, the CDC has also reported that over 2
million people in the United States develop illnesses associated with bacteria species
resistant to one or more antibiotic types each year (CDC, 2013). Consequentially, there is
now a demand for antibiotic alternatives capable of improving bird performance and
decreasing pathogen presence early in a bird’s life that is equally as efficient as
antibiotics.
Antibiotic alternatives currently being studied include probiotics. Fuller defines a
probiotic as a “live microbial feed supplement which beneficially affects the host animal
by improving its intestinal balance (1989).” Probiotics interact with the host through
1

different modes of action, which include enhancement of the gastrointestinal epithelial
barrier, the induction of competitive exclusion through increasing adhesion to the
epithelial lining, and the production of bacteriocins or lactic acid (Bermudez-Brito et al.,
2012). Common probiotic species include Bifidobacterium spp., Lactobacillus spp.,
Enterococcus spp., and Bacillus spp., and all of these species have been studied in
mammalian and avian models (Yeo and Kim, 1997; Haghighi et al., 2006; Lin et al.,
2008; Awad et al., 2009; Hassanpour et al., 2012; Jeong and Kim, 2014; Bai et al., 2017).
Lactobacillus spp. and Enterococcus spp. are commonly associated with lactic acid
production and high adhesion to the gastrointestinal tract, while Bacillus spp. and
Bifidobacterium spp. are associated with the production of antimicrobial bacteriocins
(Bermudez-Brito et al., 2012).
Previously, it has been discovered that these probiotics are capable of reducing
gastroenteric inflammation in mammalian models (Fuller, 1989; Lin et al., 2008).
Probiotics supplemented in poultry feed have also been observed to improve feed
conversion, body weight gain and immunological stimulation (Yeo and Kim, 1997;
Haghighi et al., 2006; Awad et al., 2009; Hassanpour et al., 2012; Jeong and Kim, 2014;
Bai et al., 2017). Concurrently, probiotics have exhibited immunomodulatory effects in
humans. Several probiotic species, including Bifidobacterium spp. and Lactobacillus
spp., have been shown to have anti-inflammatory effects in premature human infants
(Underwood, 2016). However, it was observed that cytokine regulation within the
intestinal epithelium, which regulates the severity of inflammatory responses, is
dependent on the probiotic species (Delcenserie et al., 2008). However, the addition of
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probiotics to feed does not address the pathogens that a chick may be exposed to at the
hatchery and during transportation to the grow-out facility.
Therefore, the in ovo injection of probiotics and synbiotics must be evaluated for
their impact on the chick’s physiological development and live performance. Although in
ovo injections are currently conducted in the industry for standard vaccinations, it is
necessary to understand whether the in ovo injection of diverse probiotic combinations
have any adverse effects on the embryo in the late stages of development (Johnston et al.,
1997). It has been discovered that the injection of individual and combinations of
probiotic cultures in ovo has the potential to be applied commercially as some probiotic
species do not negatively impact hatch (Haghighi et al., 2006; Oliveira et al., 2014;
Slawińska et al., 2014; Ploweic et al., 2015; Pender et al., 2017; Teague et al., 2017;
Triplett et al., 2018). Many of these probiotic combinations consisted of species with the
same mode of action; usually, this mode of action was lactic acid production (Haghighi et
al., 2006; Oliveira et al., 2014; Slawińska et al., 2014; Ploweic et al., 2015; Pender et al.,
2017; Teague et al., 2017).
The in ovo injection of probiotics has also been found to stimulate early immune
response and in improving bird performance (Slawińska et al., 2014; Ploweic et al., 2015;
Pender et al., 2017; Teague et al., 2017). In chickens, Płoweic et al. (2015) observed a
significant downregulation in cytokine expression after the in ovo injection of synbiotics
(probiotics and prebiotics). Similarly, Sławinska et al. (2014) observed differing
expressions of cytokines, or communicative polypeptides secreted by cells in the immune
system, in chickens when synbiotics were injected in ovo. The present knowledge about
the effect that probiotic supplementation has on immunological response mechanisms
3

indicates that probiotics may alter the host’s gastrointestinal tract in manners which are
not yet understood.
Few studies exist for studying how in ovo injected probiotics stimulate immunophysiological responses within the hatched chick (Slawińska et al., 2014; Ploweic et al.,
2015). Similarly, very few studies have tested the applicability of injecting combinations
of probiotic species with differing modes of action, such as lactic acid production coupled
with bacteriocidal actions. Additionally, the methodology of most in ovo probiotic
injection studies consisted of injecting volumes much higher than the industry standard
(50μL) by hand (Haghighi et al., 2006; Oliveira et al., 2014; Pender et al., 2017; Teague
et al., 2017). Another variable in these studies’ methods that differ from the industry is
that eggs are injected prior to incubation d 18, which is a time determined to be optimal
for in ovo vaccinations in the broiler industry (Haghighi et al., 2006; Oliveira et al., 2014;
Slawińska et al., 2014; Ploweic et al., 2015).
Since previous research has revealed the applicability of Lactobacillus animalis,
Enterococcus faecium, and Bacillus licheniformis in ovo (Allen et al., 2018; Triplett et
al., 2018), the current studies investigated two separate combinations: Enterococcus
faecium + Lactobacillus animalis and Bacillus licheniformis + Lactobacillus animalis.
Hatch performance, live performance, and immuno-physiological parameters when
challenged with coccidiosis were assessed to analyze the influence of the in ovo injection
of probiotics with differing modes of action using commercial in ovo technology.
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LITERATURE REVIEW
Antibiotics
An antibiotic is defined as an inhibitory substance that affects the growth of
different bacteria species within the same environment (Kohanski et al., 2007; Aminov,
2010). Although it is believed that humans have utilized antibiotics for centuries, the first
antibiotic was not identified until late in the nineteenth century (Aminov, 2010).
Alexander Fleming is regarded as the forefather of the antibiotic revolution where his
studies discovered the inhibitory effects of Penicillium chrysogenum, which was
determined to be from the production of penicillin (Brunel, 1951). Although Fleming’s
research was novel in many respects and earned a Nobel Prize in Physiology or Medicine
in 1945, the basis of the work was built on previous studies dating back to the 1870s (Sir
Alexander Fleming – Biographical, 2019; Brunel, 1951).
Many scientists from around the world in the late nineteenth century were on a
scientific search for an elusive breakthrough in human medicine. Although relatively
unknown, scientists such as de Bary (1879), Cornil and Babes (1885), and many others
were yielding results which indicated that bacteria species do not always exist
symbiotically. Many of these studies noted competitive exclusion properties in these
bacteria, where their growth created zones of inhibition on agar plates (Brunel, 1951).
Louis Pasteur, whose work ranged from lactic acid fermentation processes of bacteria to
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early understandings of immunology, expressed similar conclusions in his memoir where
he referred to the “antagonistic” qualities of certain bacteria species towards others in the
same environment (Brunel, 1951; Brock, 1961).
Nonetheless, the initial isolation and purification of an antibiotic from bacterial
origins shaped modern medicine as it is known today. Once isolation was proven
possible, there was a rush to develop and purify synthetic and natural antibiotic products
for therapeutic use (Walsh, 2003a). Diseases previously thought to be incurable were
found to be easily treatable with the correct antibiotic. Similarly, antibiotic treatments
began to be utilized in livestock production where the livability of an animal could be
improved with antibiotics (Castanon, 2007).

Mechanisms of action
Antibiotics are able to affect bacteria within its environment via bacteriostatic or
bacteriocidal functions; moreover, an antibiotic is either able to kill the bacteria or inhibit
metabolic processes and halt reproduction (Kohanski et al., 2007). Eukaryotic cells are
left untouched by the harmful nature of antibiotics due to their specific mechanisms of
action. Unlike eukaryotic cells, prokaryotes (such as bacteria) contain a peptidoglycan
barrier and undergo folic acid synthesis, which are both biological mechanisms attacked
by antibiotics (Walsh, 2003c). Moreover, antibiotics’ mechanisms of action are defined
through four primary cell processes in which the antibiotic attacks: cell wall synthesis,
protein synthesis, DNA replication and repair, and folate coenzyme synthesis (Walsh,
2003b).
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Disturbance in cell wall synthesis
As previously stated, the peptidoglycan layer is a vital component of a bacteria
cell, which modulates the diffusion of molecules and ions into and out of the cell.
Membrane bound proteins control the flow of the molecules through the cell as well as
provide identification markers for other bacteria cells in the environment. Antibiotics
belonging to the β-lactamase inhibitor classes (such as penicillin and cephalosporin) are
capable of disrupting the synthesis and function of the peptidoglycan layer. Through this
bactericidal mechanism, dysfunction arises within the bacteria cell and causes cell death
(Walsh, 2003c). In a study using the chemotherapeutic antibiotic, doxorubicin, it was
determined that the antibiotic effectively decreased the survivability of a leukemia cell
line by at least 10% and exhibited morphological changes that indicate the onset of
apoptosis (Ling et al., 1993). Concurrently, it was determined that doxorubicin induces
DNA degradation in the cell prior to destroying the cell membrane (Ling et al., 1993).

Disturbance in protein synthesis
The synthesis of proteins is vital for all lifeforms. Antibiotics belonging to the
macrolide and aminoglycoside classes are capable of entering the bacteria cell and
disrupting the functions of different ribosomal subunits. These disturbances include
disruption of translation through direct occupation of binding sites and disruption of
subunit assembly. Through this bacteriostatic mechanism, the antibiotic is effectively
able to interrupt the functionality of tRNA molecules, mRNA molecules, and rRNA
subunits (Walsh, 2003d). Gale and Folkes (1953) confirmed this mechanism of action,
where bacteriostatic growth inhibition was observed when Staphylococcus aureus
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cultures were incubated with differing concentrations of chloramphenicol, aureomycin,
and terramycin. Concurrently, it was observed that protein synthesis by S. aureus was
reduced in the present of chloramphenicol, aureomycin, and terramycin over time (Gale
and Folkes, 1953).

Disturbance in DNA replication and repair
Without the ability to replicate and repair DNA, a cell would be incapable of
survival (Walsh, 2003e). Therefore, antibiotics belonging to the quinolone class are
capable of disrupting enzymes essential for DNA replication and repair. Quinolones are
capable of disrupting DNA gyrase function, which causes faulty trimming of DNA
strands. In this bactericidal mechanism, the manipulation of DNA gyrase causes drastic
changes to the cell’s genetic code, which in turn causes cell death (Walsh, 2003e). In an
in vitro study by Kohanski et al. (2007), the introduction of antibiotics caused bacteria
cells to secrete hydroxyl radicals which in turn caused DNA damage to the bacteria cells,
leading to cell death 3 hours after the antibiotic treatment.

Disturbance in folate coenzyme synthesis
Often referred to as sulfa drugs, synthetic antibiotics such as sulfonamides are
capable of inhibiting a metabolic cycle specific to bacteria cells. Through the inhibition
of the dihydrofolate reductase (DHFR) enzyme, folate coenzyme synthesis is halted.
Unlike eukaryotic cells which obtain folate from food sources, bacteria cells must
synthesize folate for themselves. Therefore, by targeting this specific cycle, sulfonamides
exhibit a bactericidal mechanism (Walsh, 2003f). In an attempt to confirm existing
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theories about the sulfanomide’s mechanisms of action, McIntosh and Aberd (1939)
defined the effectivity of these synthetic antibiotics. Although the bactericidal capabilities
of sulfanomides against E. coli in mouse models and Pneumococci in blood were
determined, a 6 to 16 hours lag was observed before there was a decrease in bacterial
communities (McIntosh and Aberd, 1939).

Antibiotic use in poultry production
Once antibiotics were labeled as a miracle for human medicine, agriculturalists
became interested in the application of antibiotics in animal production. As early as 1950,
antibiotics were identified as beneficial feed additives for the poultry industry with
notable growth promotion and flock health improvements (McGinnis et al., 1957; Jones
and Ricke, 2003; Landers et al., 2012). Antibiotics (such as bacitracin methylene
disalicylate, tetracycline and virginiamycin) and anticoccidials (such as synthetic
sulfonamide products) were being actively used in poultry production prior to the
emergence of disease in a flock to improve body weight gain and prevent disease
development in young birds with weak immune systems (Chapman, 1999; Landers et al.,
2012). According to the American Meat Institute, common antibiotics used in the poultry
industry today include macrolides, tetracyclines, and ionophores (American Meat
Institute, 2014).
Intensive production practices, vertical integration, and antibiotic use for growth
promotion has made the poultry industry very effective in reducing production costs;
however, concerns have arisen over the years in regards to the development of antibiotic
resistant bacteria species from these intensive production practices (Casewell et al.,
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2003). Since the previously noted discovery of penicillin by Fleming in 1929, concerns
have always existed in regards to antibiotic resistance (Brunel, 1951). Fleming himself
noted the dangers of overusing such a potent and promising “cure-all” soon after his
initial discovery (Brock, 1961). He observed changes in the morphology as he re-cultured
pathogenic bacteria capable of growing in the presence of penicillin (Walsh, 2003g).
Today, the adaptive capabilities of pathogenic bacteria have caused great alarm in human,
companion animal, and food animal health. For example, the Center for Disease Control
and Prevention reported that over 2 million people in the United States develop illnesses
associated with bacteria species resistant to one or more antibiotic types each year (CDC,
2013).
It is now common knowledge that the extensive use of subtherapeutic dosages of
antibiotics can lead to antibiotic resistance in both pathogenic and commensal bacteria
(Aminov, 2010; Giedraitiene et al., 2011). Bacteria are able to mutate their genetic
information to develop antibiotic resistant characteristics then transfer this genetic
information from cell to cell (Aminov, 2010; Giedraitiene et al., 2011). Consequently,
antibiotic resistance exhibited by bacteria species has developed in three diverse methods.
The antibiotic resistant bacteria either inactivate the antibiotic intracellularly, force
antibiotics out of the cell through efflux pumps, or modify the antibiotic target within the
cell through methylation, phosphorylation, acetylation, or adenylation so that it is
unrecognizable to that antibiotic (Walsh, 2003g). Previous studies have observed that
bacterial isolates from poultry, such as Salmonella spp. and Campylobacter spp.,
exhibited antibiotic resistance characteristics that may cause illness if presented to
humans (Cui et al., 2005; Mathew et al., 2007). Similarly, commensal bacteria (such as
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Lactobacillus spp.) in the gastrointestinal tract of poultry exhibited resistance towards
vancomycin and teicoplanin (Salah et al., 2012).
Due to the rising number of cases linked to antibiotic resistant bacteria in human
health and evidence of antibiotic resistant bacteria species in food animal production, the
European Union created a ban on subtherapeutic antibiotic feed additives in animal
agriculture in 2005 (Castanon, 2007). The European Union also banned several
anticoccidial feed additives in 2013 (Castanon, 2007). The restrictions on antibiotic use in
the European Union may potentially impact the international trade of poultry products,
and this led the United States to take its own steps towards regulating antibiotic use in
food animals (Castanon, 2007; Centner, 2016). New Veterinary Feed Directives (VFDs)
were created in 2013 to aid in controlling antibiotic and anticoccidial applications; these
measures ensure that a veterinarian has total control of prescribing antibiotics for disease
rather than growth promotion (Centner, 2016).

Probiotics as an antibiotic alternative
Probiotics are defined as live microorganisms that maintain a symbiotic
relationship with their host by improving intestinal microbiota (Fuller, 1989). In light of
the demands for antibiotic free production practices, probiotics are one of the research
focuses for their viability as an antibiotic alternative. Previous research has discovered
that probiotics may beneficially influence the gastrointestinal tract of its host through
diverse modes of action which regulate inflammatory responses (Fuller, 1989; Lin et al.,
2008; Underwood, 2016). Through these differing modes of action, probiotics are able to
alter the environmental conditions of the gastrointestinal tract (Bermudez-Brito et al.,
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2012). Several common probiotic species applied in mammalian and avian hosts include
Lactobacillus spp., Enterococcus spp. and Bacillus spp. (Yeo and Kim, 1997; Haghighi et
al., 2006; Lin et al., 2008; Awad et al., 2009; Hassanpour et al., 2012; Jeong and Kim,
2014; Underwood, 2016; Bai et al., 2017).

Modes of action
As previously stated, probiotics exhibit three distinct modes of action that are
capable of modulating the immune system, enhancing the integrity of the intestinal
epithelium, and altering the composition of the microbiota (Fuller, 1989; Bermudez-Brito
et al., 2012; Plaza-Díaz et al., 2018). These modes of action include lactic acid secretion,
bacteriocin production, and adhesion to the epithelial lining (Bermudez-Brito et al.,
2012). A probiotic participates in an ecological process referred to as competitive
exclusion through these differing modes of action. Charles Darwin first defined the initial
concepts for competitive exclusion in his book The Origin of Species (1859). In his book,
Darwin (1859) stated, “we can see that when a plant or animal is placed in a new country,
among new competitors, the conditions of its life will generally be changed in an
essential manner.” Georgy Gause, whose interests applied to varying fields of ecology,
began research in the concept of competitive exclusion in the 1930s (Kodash and Fischer,
2018). His studies with protozoan species were the first to definitively prove the validity
of the competitive exclusion principle, and his discovery has led to the principle being
coined “Gause’s Principle of Competitive Exclusion” (Kodash and Fischer, 2018). Since
then, many studies analyzing the competitive exclusion principle have been conducted in
various fields of ecology, including those in microbiology (Chan et al., 1985; Zhao et al.,
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2004; Callaway et al., 2008). Probiotic bacteria utilize the competitive exclusion principle
to reduce pathogenic bacteria species in the same environment through the utilization of
the various modes of action.

Organic acid production
Organic acid production is a common trait observed in many probiotic bacteria
species (Hutkins and Nannen, 1993). The secretion of organic acids, such as lactic acid, is
effective in decreasing the pH of the surrounding environment (Hutkins and Nannen,
1993). It has been determined in both food processing and gastrointestinal health studies
that by decreasing the pH of an environment, it is possible to reduce pathogenic bacteria
species (Hutkins and Nannen, 1993; Balcázar et al., 2007). For example, Hansen et al.
(2007) observed that the supplementation of organic acids in the feed of weaned piglets
was capable of decreasing gut pH and regulating Lactobacillus populations within the
stomach. Similarly, Balc (2007) yielded results that indicate that lactic acid producing
bacteria exhibit antimicrobial abilities which decrease the presence of pathogens in the
same environment.

Bacteriocin production
According to the definition by Merriam-Webster, a bacteriocin is “an antibiotic
produced by a bacteria (Bacteriocin, 1954).” In technical terms, bacteriocins are
bacteriocidal or bacteriostatic polypeptides secreted by different species of bacteria as a
by-product of metabolic activities (Dobson et al., 2011). It is known that bacteriocins are
produced by gram positive and gram negative bacteria species and vary significantly in
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function and size (Klaenhammer, 1988). The production of bacteriocins is not a trait that
belongs to one specific bacteria genus; most bacteria, even those who secrete lactic and
organic acids, produce bacteriocins (Klaenhammer, 1988; Bermudez-Brito et al., 2012).
Previous studies have observed that bacteriocin production is capable of altering the
bacterial populations in the surrounding environment in in vitro studies (Corsetti et al.,
2003; Dawid et al., 2006; Strompfová and Lauková, 2007; Camargo et al., 2015). In
addition, the production of bacteriocins may be one causative agent for
immunomodulation within the gastrointestinal tract of the host (Walsh et al., 2008).

Adhesion to the epithelium
The capability for a probiotic to adhere to the epithelial lining is essential for
maintaining its presence in the gut for extended periods of time. Fuller (1989) noted that
the presence of epithelium-bound lactic acid-producing bacteria in pigs and poultry may
be an example of the need for adhesive abilities in probiotics to reduce pathogen
presence. Similarly, previous studies observed that lactic acid-producing bacteria, such as
Bifidobacterium spp., are capable of exhibiting adherence to the human gastrointestinal
epithelium as well as decrease the adherence of pathogenic bacteria such as Clostridium
spp., Listeria spp., and Staphylococcus spp. (Collado et al., 2005). Morelli et al. defines
the adhesive abilities of lactic acid bacteria as an “adaptation to the intestinal
environment,” where probiotics such as Lactobacillus spp. secrete adhesins (protein
compounds) which allow for anchoring to the intestinal mucin (2012; Juge, 2012;
Forestier et al., 2000). By adhering to the intestinal lining and producing substances such
as organic acid and bacteriocins, several studies recognized that adhesion allows direct
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modulation of the host’s mucosal immune system (Hirano et al., 2003; Delcenserie et al.,
2008; Mountzouris et al., 2010).

Common probiotic species
As previously stated, it has been observed that different probiotic species exhibit
different modes of action that influence the presence of other bacteria species, including
those that are pathogenic, in the immediate environment. Although hundreds of probiotic
bacteria species exist, four genera commonly associated with use in animal agriculture
include Bifidobacterium spp., Lactobacillus spp., Enterococcus spp., and Bacillus spp.

Bifidobacterium species
The Bifidobacterium spp. is commonly associated with their ability to produce
organic acids such as acetic acid, lactic acid, formic acid, and succinic acid (Tannock,
1992). During its early discovery and differentiation from other bacteria, Bifidobacterium
was noted to produce fructose-6-phosphoketolase for carbohydrate metabolism (Gupta et
al., 2017). Delgado et al. (2008) observed that the species of Bifidobacterium varies in
their survivability in the presence of bile salts, low pH levels (3.0-4.0), and antibiotics.
Interestingly, the analysis by Delgado et al. (2008) found that several Bifidobacterium
strains (including B. longum L25 and B. catenulatum L21) exhibited elevated minimum
inhibitory concentrations (MIC) to several antibiotics, indicating that these
Bifidobacterium spp. require higher concentrations of specific antibiotics to exhibit a
reduction in growth. Similar results were obtained by another study where
Bifidobacterium isolates from the human gastrointestinal tract yielded varied tolerances
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to low pH (3.0) and bile salt depending on the bacteria strain and growth media used
(Mättö et al., 2004). Delgado also observed that several strains of Bifidobacterium
(including Bifidobacterium animalis, a species commonly found in food animal
gastrointestinal systems), exhibited inhibitory effects on several pathogenic bacteria
species (Delgado et al., 2008; Lu et al., 2003). Previous research has isolated species of
Bifidobacterium from the ileum and ceca of broiler chickens, with populations of
Actinobacteria bacteria class (the class of bacteria which Bifidobacterium spp. belong to)
increasing after d 7 of life (Lu et al., 2003; Ballou et al., 2016).

Lactobacillus species
The modes of action for Lactobacillus are commonly known to be lactic acid
secretion and competitive exclusion capabilities (Hutkins and Nannen, 1993).
Lactobacillus spp. are gram positive, non-spore forming cocci that secrete lactic acid into
their external environment (Tannock, 1992). Previous studies have found that lactic acid
secretion by Lactobacillus spp. regulates environmental pH, which in turn makes the
environment incompatible with many pathogenic bacteria species (Hutkins and Nannen,
1993). Concurrently, Lactobacillus spp. are noted for their highly adhesive abilities that
allow the bacteria to attach to the epithelial lining of the gastrointestinal tract and
maintain a presence within the system (Tannock, 1992; Gusils et al., 2003; Barrangou et
al., 2012). Gusils et al. (2003) observed that Lactobacillus spp. exhibited highly adhesive
abilities at a pH of 7.0; however pathogenic bacteria, such as Salmonella pullorum, were
capable of inhibiting Lactobacillus spp. adhesion to the epithelium. From isolated
bacteria of duck digesta, Ehrmann et al. (2002) observed variances in the adhesion of
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seven separate species of Lactobacillus to epithelial cells. It was also observed that
Lactobacillus spp. exhibited a preference towards adherence on the crop epithelial cells,
rather than epithelial cells from other locations of the gastrointestinal tract (Ehrmann et
al., 2002). In broilers, large populations or Lactobacillus spp. have been identified in the
duodenum, jejunum and ileum of the small intestines (Lu et al., 2003). Concurrently,
Ballou et al. (2016) observed increases in Lactobacillus spp. from d 14 to 28 of life in the
ceca of broiler chicks.

Enterococcus species
Similar to Lactobacillus spp. and Bifidobacterium spp., the primary modes of
action for Enterococcus spp. is lactic acid production and bacteriocin secretion (Tannock,
1992). Enterococcus spp. are gram positive, non-spore forming cocci that produce lactic
acid (Tannock, 1992). Enterococci have also been found to secrete bacteriocins capable
of inhibiting microbial activity in the bacteria surrounding them (Tannock, 1992; Araujo
and Ferreira, 2013). Enterococcins, or bacteriocins secreted by Enterococcus spp.,
include gelatinase, cytolysin and hyaluronidase; all of these enterococcins play an
integral role in degrading cell walls (Araujo and Ferreira, 2013). Although potentially
pathogenic in nature, subspecies of Enterococcus exhibit probiotic properties within a
host (Tannock, 1992; Araujo and Ferreira, 2013). In a study by Strompfová et al. (2007),
Enterococcus spp. isolated from chicken gastrointestinal tracts exhibited an intolerance to
bile salts but high adherence to the intestinal mucin of multiple species, such as canines,
humans, and porcines. It was also observed that bacteriocin production by different
Enterococcus spp. is dependent on media type, with MRS appearing to yield the greatest
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production of bacteriocins by Enterococcus spp. (Strompfová et al., 2007). In broiler
chickens, Enterococcus species have been previously identified in the ileum of the small
intestines (Lu et al., 2003).

Bacillus species
The primary mode of action for Bacillus spp. is bacteriocin secretion (Cutting
2010). Bacillus spp. are gram positive, spore-forming rod that secretes bacteriocidal and
bacteriostatic bacteriocins (Cutting, 2010). Its ability to form spores makes Bacillus a
desirable probiotic species for in-feed probiotic applications in the poultry industry as it
would be heat and pH resistant in its sporulated state (Hoa et al., 2000; Leser et al., 2007;
Cutting, 2010). However, Hoa et al. (2000) observed that the viability of a spore under
high-heat conditions is dependent on the strain of Bacillus subtilis used in the experiment.
In this study, Hoa et al. (2000) also determined that several strains of Bacillus subtilis
exhibited resistance to multiple antibiotics. Bacillus has many known classes of
bacteriocins that have been well documented to induce bacteriostatic and bacteriocidal
behaviors (Abriouel et al., 2010). In a study of the bacteriocins produced by B.
licheniformis, it was observed that the secreted bacteriocins did not impact the pH of the
bacteria’s environment but did exhibit inhibitory capabilities towards B. cereus, L.
monocytogenes, and Streptococcus spp. (Cladera-Olivera et al., 2004).

Although Cladera-Olivera et al. (2004) defined these inhibitory proteins as
“bacteriocin-like substances”, recent studies attempted to identify characteristics of
bacteriocins that are unique to B. licheniformis strains (Dischinger et al., 2009;
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Shobharani et al., 2015). Shobharani et al. (2015) isolated two strains of B. licheniformis,
where one strain secreted a bacteriocin that affected bacteria cell wall integrity while the
other strain impacted RNA synthesis. Interestingly, previous research also revealed that a
B. licheniformis strain is capable of producing at least two antimicrobial bacteriocins at
once (Dischinger et al., 2009). Therefore, further research is necessary to accurately
define the secretion of bacteriocins in different B. licheniformis strains.

It is important to note that some Bacillus spp., including B. cereus, are pathogenic
species which have previously exhibited highly adhesive abilities on epithelial surfaces of
the gut and resistance to high concentrations of antibiotics (Bernhard et al., 1978; Faille
et al., 2002). It was observed that many Bacillus spp. are found within the ceca of the
broiler chicken (Lu et al., 2003).

Therapeutic uses of probiotics
Extensive research has been conducted to analyze the capabilities of probiotics in
reducing gastroenteric inflammation in both humans and food animals (Yeo and Kim,
1997; Haghighi et al., 2006; Lin et al., 2008; Awad et al., 2009; Hassanpour et al., 2012;
Jeong and Kim, 2014; Bai et al., 2017). For example, the consumption of lactic acid
producing bacteria species decreased inflammatory reactions in premature infants
(Underwood, 2016). With evidence of immunomodulatory capabilities in many animal
models, the applications of probiotics in the commercial poultry industry are being
considered. The application of in-feed probiotics have shown to be an effective antibiotic
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and anticoccidial alternative for the poultry industry due to their bacteriostatic and
bacteriocidal properties.
Although studies observed that probiotics in feed are not equal in growth
promotion when compared to in feed applications of antibiotics, this does not mean that
their beneficial attributes should be ignored (Rahimi and Khaksefidi, 2006; Mountzouris
et al., 2007; Tsirtsikos et al., 2012). Aliakbarpour et al. (2012) provided inclusions of
Bacillus subtilis and lactic acid-producing probiotics in broiler feed and found that these
inclusions can increase body weight gain as well as stimulate gastrointestinal mucin gene
expression, which may aid with nutrient absorption. The inclusion of lactic acid bacteria
cocktails at varying levels in feed appear to effectively alter the gastrointestinal
morphology in the posterior portions of the small intestines of chickens (Awad et al.,
2009; Tsirtsikos et al., 2012). Multiple studies observed beneficial effects in live
performance when Bacillus subtilis is supplemented in feed (Jeong and Kim, 2014; Bai et
al., 2017). Similarly, other studies observed the positive effects of lactic acid producing
bacteria, such as Enterococcus spp. and Lactobacillus spp., on the growth performance of
commercial broiler strains (Mountzouris et al., 2007; Awad et al., 2009; Aliakbarpour et
al., 2012). Therefore, it has been defined in several models that probiotics are effective in
modulating the gastrointestinal system for disease prevention and improving growth
(Mountzouris et al., 2007; Lin et al., 2008; Awad et al., 2009; Tsirtsikos et al., 2012;
Aliakbarpour et al., 2012; Jeong and Kim, 2014; Bai et al., 2017).
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Challenges in maintaining chick health
Disease development in broiler production has major impacts on broiler
performance and human food safety. Early onset of disease while birds are still young has
major implications for the performance of the flock later in production (Dibner et al.,
1998). As previously stated, antibiotics have been extensively used in the industry at
subtherapeutic levels to promote efficient bird growth while managing bacterial disease
threats present within the grow-out facility. Although antibiotics are currently being used
therapeutically in poultry production practices, those especially critical for human
medicine require a VFD prior to treatment (FDA, 2018). The subtherapeutic use of
antibiotics was a buffer to manage the potential threats to early chick health, and now
chicks may be more susceptible to several prominent bacterial and protozoan diseases
early in life that are detrimental to flock health.

Disease threats in the hatchery
Although environmental influences in the broiler house can influence bird health,
there are several bacterial infections linked to the hatchery. Salmonella serovars are a
common disease associated with poultry that leads to foodborne pathogens and clinical
infections (Bradbury, 2008). Although infections by Salmonella spp. only impact bird
health and performance in chicks under 14 days of age, mature breeder flocks can be
carriers of Salmonella. This can lead to vertical transmission of Salmonella enteritidis
from the hen to the egg, which is a common cause of Salmonellosis in chicks
(Thiagarajan et al., 1994; Bradbury, 2008). Therefore, the hatchery is considered a major
origin in the transmission of Salmonella spp. in broiler production. Whether the presence
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of Salmonella serovars are on the shell or within the egg, incubation of contaminated
eggs in the hatchery can lead to the contamination of hatchery equipment and the
infection of newly hatched chicks (Kim and Kim, 2010). Salmonellosis commonly causes
high morbidity and low mortality, which causes very poor bird performance and stunted
growth (Bradbury, 2008).
Another common bacterial pathogen present in the hatchery is Escherichia coli
(Cortes et al., 2004; Giovanardi et al., 2005; Kim and Kim, 2010). It was discovered that
serovars of E. coli commonly found in broiler breeder houses are the same found in the
unhatched, dead embryos and infected chicks (Rosario et al., 2004). Concurrently,
hatchery surfaces and air flow can be easily contaminated with Escherichia spp. as it has
previously been found on newly hatched chick fluff (Gehan, 2009; Kim and Kim, 2010).
E. coli is one of several bacterial pathogens associated with omphalitis in newly hatched
chicks; it is known to cause high chick mortality and poor chick performance within the
first week of life (Reid et al., 1960). Although treatable, many E. coli isolated from
infected yolk sacs were found to be antibiotic resistant (Nasrin et al., 2012).
Aspergillosis is another disease that is a constant concern in chick health. The
Merck Veterinary Manual defines aspergillosis as a respiratory disease caused by
Aspergillus fumigatus, which develops within the first 6 weeks of a bird’s life and is
common in domestic and wild avian species (Hoerr, 2019). It is a disease commonly
associated with poor hygienic conditions in a hatchery or grow-out facility (Ghori and
Edgar, 1973; Hoerr, 2019). Wright et al. (1960) determined that the fungal spores can
impact the embryo if present in an incubator, in turn leading to labored breathing and
fungal spores in the lungs and interior portions of the shell after hatch. When severe
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infection exists, lesions can be observed through out the entire respiratory system as well
as the liver (Hoerr, 2019). If the chick survives the infection, ascites and airsacculitis are
commonly observed during processing (Julian and Goryo, 1990; Hoerr, 2019).

Due to aspergillosis being commonly associated with the hatchery, concerns have
arisen with Aspergillus fumigatus and the use of in ovo technology. For example,
Williams et al. (2000) observed that through in ovo injection, the air cell of the egg might
exhibit a heightened threat to Aspergillus spores present in the incubator. Therefore,
much emphasis has been placed on hatchery sanitation as commercial hatcheries continue
to become more advanced (Mauldin, 1993; Johnston et al., 1997; Gehan, 2009; Kim and
Kim, 2010).

Coccidiosis
Outside of the hatchery, young birds are also susceptible to a particularly
detrimental gastroenteric disease caused by a protozoan species. Coccidiosis is one of the
primary gastrointestinal diseases in a growing bird that negatively affects flock
performance and health (Edgar, 2007; Gussem, 2007). As of 2007, it is estimated that
coccidiosis cost the United States poultry industry approximately $700 million annually
(Edgar, 2007). Coccidiosis is caused by an infection of the Eimeria spp., which
sporulates in litter and develops in the gastrointestinal tract of its host upon its
consumption. The sporulated oocysts adhere to the epithelial lining of the intestinal tract
of the bird and ruptures the intestinal epithelial cells as the coccidia mature (Edgar,
2007).
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There are 9 species of Eimeria associated with coccidiosis infections: E. tenella,
E. necatrix, E. maxima, E. brunetti, E. acervulina, E. mivati, E. mitis, E. hagani and E.
praecox. Of these, E. tenella, E. maxima and E. acervulina are the most common in
broiler production (Edgar, 2007). Each Eimeria spp. allocates to their own respective
region of the gastrointestinal tract with E. tenella found in cecal pouches, E. maxima in
the jejunum and ileum, and E. acervulina in the duodenum (Edgar, 2007). The damage,
or lesions, created by Eimeria spp. is especially detrimental to bird health due to
Clostridium perfringens infections that occur after the rupture of epithelial cells, leading
to necrotic enteritis (Collier et al., 2008).

Immune system of poultry
The immune system is a vital component of embryo development that is
systemically involved in the prevention of pathogen presence within the chick
(Christensen, 2009). Although a newly hatched chick has a fully developed circulatory,
skeletal, digestive and respiratory system, the immune system is not completely
competent until nearly 21 days after hatch (Christensen, 2009; Schijns et al., 2014). The
poultry industry has been reliant on antibiotics and rigorous vaccination programs to
maintain chick health after hatch. However, the transition to antibiotic-free production
has left a gap in production practices and leaves the chick with only its immune system as
its only defense to fight against pathogens in the environment. Therefore, an
understanding of the chick’s immune system and factors that influence it is necessary.
Prior to any introduction to its external environment, vertebrate embryos will also receive
components of immunity from their mother (Hasselquist and Nilsson, 2009). At birth,
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most vertebrates have immune systems that can be separated into two distinct parts:
innate immunity and adaptive immunity (Glick, 1986; Kaspers et al., 2014).

The innate immune system
All organisms, whether vertebrate or invertebrate in nature, contain innate
immune systems. Innate immunity is composed of physical protection barriers (such as
the skin or gastrointestinal epithelium) and leukocytes, which locate pathogens and
prevent a systemic infection within a host (Kaspers et al., 2014). The innate immune
system is commonly regarded as an organism’s first line of defense against an antigen,
which developed over centuries of evolutionary pressure (Parkin and Cohen, 2001).
Through the inflammatory response by leukocytes, the phagocytic properties of cells in
the innate immune system attract cells from the adaptive immune system to the site of
infection for further degradation of pathogenic agents and development of immunological
memory (Beutler, 2004).
Leukocytes, or white blood cells, associated with the mammalian innate immune
system include lymphocytes, monocytes, and granulocytes (such as neutrophils,
basophils, and eosinophils). In avian and reptilian species, the neutrophil-type
granulocyte is referred to as a heterophil. Both neutrophils and heterophils carry out
similar tasks within a host (Glick, 1986; Epelman et al., 2014). Macrophages, which are a
derivative of monocytes, and granulocytes are known for their phagocytic properties
within a host. Physiologically, macrophages can be found within many tissues including
the thymus, spleen, liver, and lungs (Glick, 1986; Epelman et al., 2014). Granulocytes
generally exhibit a short lifespan and solely exist in circulating blood (Glick, 1986).
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Similarly, each white blood cell type reacts to specific types of infections. Macrophages
promote the first inflammatory response through secreting signaling proteins (referred to
as cytokines) to attract specific granulocytes (Parkin and Cohen, 2001). Granulocytes
also exhibit specificity in the pathogens they attack. For example, neutrophils/heterophils
attack microbial pathogens, eosinophils attack parasitic pathogens, and basophils are
commonly associated with severe inflammatory responses such as anaphylaxis (Parkin
and Cohen, 2001).
These leukocytes are capable of identifying pathogenic microorganisms through
membrane-bound proteins called toll-like receptors (TLRs). TLRs recognize several
unique attributes only found in bacteria: methylation of the first amino acid used for
translation, peptidoglycan walls, lipopolysaccharide layer, flagellum, membrane bound
receptors, and unique bacterial DNA fragments (Alberts et al., 2002). Once a pathogen
has been detected by a macrophage or granulocyte, the leukocytes attempt to phagocytize
the pathogen. During this process, the leukocyte secretes acidifying compounds and
degradation peptides capable of destroying the cell walls and genetic material of the
pathogenic microbes (Alberts et al., 2002). Upon the phagocytosis of a pathogen, the
leukocyte secretes cytokines or presents an active receptor to the cells of the adaptive
immune system to develop immunological memory or further undergo cell lysis (Glick,
1986).

The adaptive immune system
Adaptive immunity consists of B cells, T cells, and the destructive peptides and
enzymes that they secrete for recognition and destruction of threats to the host’s body
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(Glick, 1986; Schijns et al., 2014). These components are interconnected in a manner that
makes the adaptive immune system very effective in eliminating threats within the body.
Although connected, the adaptive immune system is separated into two components:
humoral immunity and cell mediated immunity (Glick, 1986). B cells, who are essential
for immunoglobulin synthesis, are part of humoral immunity. T cells, who initiate B cell
function and undergo cytotoxic activities, are part of cell-mediated immunity (Glick,
1986).
Humoral and cell-mediated immune responses are reliant on the initial response
of the innate immune system, and it is hypothesized that these aspects of adaptive
immunity are evolutionary developments from the innate immune system that are present
in most vertebrate organisms (Parkin and Cohen, 2001). In most organisms who have
adaptive immune systems, B cells originate from bone marrow and T cells originate from
the thymus. These cells relocate to a site of infection identified by leukocytes, where they
use the major histocompatibility complex to identify and degrade the antigen and develop
a specific, immunological memory (Glick, 1986; Parkin and Cohen, 2001).
In avian species, B cell development occurs in another lymphatic organ other than
bone marrow. Glick et al. (1956) discovered that the bursa of Fabricius, a small organ
found at the base of a bird’s cloaca, is crucial for immune system development and
immunoglobulin synthesis in birds (Glick et al., 1977). Each bursa fold is comprised of
follicles that initiate B cell hematopoiesis (Glick, 1986). Olah and Glick (1978) estimated
that each bursa contains 8,000 to 12,000 follicles, all of which are capable of synthesizing
B cells simultaneously. Although five different immunoglobulin isotypes have been
identified in other organisms (IgM, IgG, IgA, IgD, and IgE), only IgM, IgG, and IgA
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have been identified in birds (Glick, 1986). Previously it has been noted that B cells are
present in the body after bursectomy, indicating that B cells are also produced in other
lymphatic tissues in the body (Granfors et al., 1982). However the bursa may be essential
for the differentiation of B cells (such as plasma cells and memory B cells; Granfors et
al., 1982).
For T cells, it is universally accepted that their proliferation and differentiation
occurs within thymic tissues (Glick, 1986; Lowenthal et al., 1994; Erf, 2004; Shaw et al.,
2018). In the thymus, T-precursor cells differentiate into CD4+ T helper cells, CD8+ T
cytotoxic cells, and natural killer cells (Erf et al., 2004). T helper cells assist B cells in
antibody production, cytotoxic T cells actively attack antigens through recognition using
the major histocompatibility complex, and natural killer cells attack antigens through
methods other than those used through the major histocompatibility complex (Lowenthal
et al., 1994; Erf et al., 2004). Therefore, the main tasks of T cells include stimulating the
synthesis of immunoglobulins, stimulating inflammatory responses within the body and
suppressing inflammatory responses within the body (Glick, 1986).

Inflammation
The Latin origins of the word “inflammation” is from the root word inflammare,
which is translated to “to set on fire (George, 2006).” In medicinal terms, inflammation is
defined by Graeme and Majno (1977) as the “response of living tissue to local injury; that
leads to the local accumulation of blood cells and fluid; and … its primary significance
being (in all likelihood) that of a defense against microscopic invaders.” Inflammation
occurs after a physical wound, viral infection, or bacterial infection develops within a
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tissue, where a cascade of events occur which collect cells to the affected region (Ashley
et al., 2012). The initial step in an inflammatory response is vasodilation, where red blood
cells, leukocytes, and plasma proteins rapidly travel to the site of injury (Huang and Vita,
2006). These cells pass through the endothelial cells of the blood vessels and collect
around the injury (Fillippo et al., 2013). This passage of white blood cells through the
blood vessel and into the tissue is called diapedesis and is usually accompanied with fluid
buildup around the injured tissue referred to as edema (Kalogeris et al., 1999; Friedl and
Weigelin, 2008). The influx of cells and fluid to the affected area is accompanied with
localized heat and swelling (Bowdre et al., 1981). After the injury and/or infection is
resolved, scarring will develop at the site of the wound (Ashley et al., 2012).
As previously stated, leukocytes such as neutrophils/heterophils and macrophages
travel to the site of the wound to begin phagocytic and destructive activities that in turn
attract T cells and B cells from the adaptive immune system (Ashley et al., 2012).
Although inflammation is destructive towards the affected tissue, its intention is to be
proactive in resolving a hazard to the body and is a process observed in both unicellular
and multicellular organisms (Ashley et al., 2012). Through the release of cytokines by
white blood cells, tissue cells, B cells, and T cells, the body is able to regulate
inflammatory responses and reduce damage caused to tissue by inflammation (Wigley
and Kaiser, 2003).

Cytokines
Wigley and Kaiser (2003) define cytokines as proteins that are “secreted by cells
that play an important role in the activation and regulations of other cells and tissues
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during inflammation and immune response”. However, cytokines not only regulate
immunological function; they are also responsible for the regulation of embryonic
development, tissue repair, and aging (Dinarello, 2014). These peptides are able to
regulate cell activity in all cell types except for red blood cells through recognition of
receptors on the surfaces of other cells within the body (Wigley and Kaiser, 2003;
Dinarello, 2014). Cytokines are separated into primary families, all of whom exhibit
unique immunological functions: interleukins (IL), colony-stimulating factors (CSF),
interferons (INF), transforming growth factors (TGF), tumor necrosis factors (TGF), and
chemokines (Vilček, 2003).

Cytokines assist in many immunological functions within a host, including
regulation of inflammation in tissues (through pro-inflammatory and anti-inflammatory
mechanisms) and regulation of immune cell proliferation (Wigley and Kaiser, 2003;
Lillehoj et al., 2004; Dinarello, 2014). Merriam-Webster defines pro-inflammatory and
anti-inflammatory in the following manner: pro-inflammatory is the promotion of
inflammation, while anti-inflammatory is the counteraction against inflammation (Proinflammatory, 2007; Anti-inflammatory, 1736). These cytokines are capable of
interacting with different cells throughout the body through receptors circulating
(soluble) receptors and membrane-bound receptors (Heaney and Golde, 1996). Soluble
cytokine receptors are very common, and previous research has noted that an
upregulation, or increase, in cytokine levels in tissues corresponds with an upregulation
in their respective circulating soluble receptors (Aukurst et al., 1994; Bloch et al., 2018).
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Embryonic development and immunity
Cellular differentiation within the embryo plays a crucial role in immunological
development. Differentiation is defined by Loeffler (1997) as a “qualitative change in the
cellular phenotype that is the consequence of the onset of synthesis of new gene
products”. Within an organism, all cells differentiate from stem cells during embryonic
development. Cells associated with the immune system develop from multipotent
hematopoietic stem cells (Kumar and Jack, 2006). These stem cells differentiate into
myeloid progenitors and lymphoid progenitors. Under the myeloid progenitor cells, the
progeny belong to circulating blood cells, including megakaryocytes, erythrocytes, mast
cells, and myeloblasts. Circulating white blood cells, such as basophils, neutrophils,
eosinophils, and monocytes, originate from myeloblasts. Also, monocytes differentiate
into the phagocytic macrophage and dendritic cells. Under the lymphoid progenitor cells,
the differentiated cells include natural killer cells and small lymphocytes. From small
lymphocytes, B cells and T cells develop (Kumar and Jack, 2006).
The process of embryonic development plays a role in the early regulation of an
embryo’s immune system. Patten (1951), who provides extensive detail on the embryonic
development of a chicken, explains that vasculation of the embryo occurs by 29 hours of
incubation. By day 3 and day 4 of incubation, the embryo has developed a primitive
gastrointestinal system and exhibits extensive circulation within the egg (Patten, 1951).
The lymphatic system appears to begin to develop by day 7 of embryonic development,
where lymphatic tissue is observed in the pelvic region and neck region (Huettner, 1949).
By day 13, T cells and B cells are present within the embryo (Lucas and Jamroz, 1961). It
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can be assumed that these lymphatic tissues are evidence of early tissue proliferation for
the bursa of Fabricius and thymus organs (Glick, 1986).
The development of the bursa of Fabricius and the thymus, two immunological
key organs for adaptive immune response, are essential for the embryo’s ability to
develop immune memory and immunocompetence (Glick, 1986). As previously stated, B
cells are secreted by the bursa and are associated with antibody-related immune response
mechanisms (Glick, 1986). Glick et al. (1956) determined that the bursa of Fabricius
modulates the production of B cells within the bird during the early stages of chick
development post-hatch as well as during embryonic development (Glick, 1986). This is
a critical discovery due to immunoglobulins, or antibodies, being essential for pathogen
destruction within a host (Glick, 1986). Previous research notes that maternal antibodies
for common poultry diseases are transferred from the hen to the egg, and consequently
the hatched chick, to aid in neonatal immune response (Gharaibeh et al., 2008; Schijns et
al., 2014). T cells and B cells are notably present in the embryo by d 13 of incubation
(Lucas and Jamroz, 1961; Glick, 1986).

Maternal immunity
Prior to birth, many organisms receive an initial immunological boost from their
mother (Hasselquist and Nilsson, 2009). Often referred to as maternal immunity, this
form of protection provides the young organism with base-line protection through
maternally provided antibodies specific for pathogens in the external environment.
Through the passing of maternal antibodies, it has been previously observed that the
young organism is more capable of combatting and recovering from specific pathogens
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(Gharaibeh et al., 2008; Gharaibeh and Mahmoud, 2013; Lauritsen et al., 2017; Peel et
al., 2018). In placental mammals, such as swine and bats, evidence has been found which
supports the fact that a mother is capable of transferring immunological memory through
antibodies for specific viruses and bacteria that she encountered prior to giving birth
(Lauritsen et al., 2017; Peel et al., 2018). Lauritsen et al. (2017) observed that sows
challenged with Mycoplasma hyosynoviae prior to pregnancy gave birth to offspring less
receptive to their own M. hyosynoviae challenge. Similarly, Peel et al. (2018) observed
that populations of bats appear to pass maternal immunity through antibodies by noting
serological changes in newly born pups when compared to their parents who were
infected with hepinavirus or Lagos Bat Virus.
Maternal immunity also exists in avian species, even though the embryo does not
experience a constant contact with its mother during embryonic development and does
not nurse from its mother upon hatch (Hasselquist and Nilsson, 2009). Although it is
confirmed that multiple antibodies are present in the egg yolk and plasma of a hen’s
progeny, research has shown that these antibodies decay and leave a gap in the chick’s
immunological development (Sahin et al., 2003; Hamal et al., 2006; Gharaibeh and
Mahmoud, 2013; Yosipovich et al., 2014). Sahin et al. (2003) observed that 3 day old
broiler chicks have specific antibodies for Campylobacter spp. from their mothers. By
day 21, Sahin et al. (2003) observed that this specific maternal antibody was not present
in those same broiler chicks and led to greater susceptibility to a Campylobacter jejuni
challenge.
Maternal influence is present within the egg up until hatch, although these
influences can not be maintained over the course of the chick’s life (Sahin et al., 2003;
36

Yin et al., 2010; Gharaibeh and Mahmoud, 2013; Yosipovich et al., 2014; Nyangahu et
al., 2018). The transfer of maternal antibodies and bacteria may be through transovarian
transmission, where the hen transfers antibodies and bacteria from her reproductive tract
to the egg that she is forming (Mishu et al., 1991; Berchieri et al., 2010; Cox et al., 2012).
For example, Deeming (2006) observed that bacteria is present in the yolk sac of
hatchlings from multiple avian species. This is notable, as the yolk sac acts as the
umbilical cord for the avian embryo, where all nutrients from the hen are present for the
embryo to utilize throughout development (Huettner, 1949).
Although the transmission of antibodies and bacteria from the hen to the egg is
beneficial, chicks hatched in commercial poultry production do not experience any
contact with the hen. In wild-type birds, the chick hatches out into a nest. It has been
discovered that the microbiological components of the nest of wild-type birds affect the
microbiological communities on eggshells, which in turn influences the bacteria
populations that the newly hatched chick may come into contact with upon hatch (Brandl
et al., 2014; Martínez-García et al., 2016). This type of environment is vastly different
from the sterile environment that a chick is presented with when it hatches out in a
commercial poultry hatchery (Kim and Kim, 2010). Therefore, this lack of maternal
contact within the nest may influence some vital components of post-hatch maternal
immunity in commercial poultry production.

In ovo vaccination and its impact on the immune system
Although lymphatic tissues begin to develop by day 7 of embryonic development
and T and B lymphocytes are present in the blood system by d 13 of embryonic
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development, the chick is not considered immunocompetent until several weeks after
hatch (Huettner, 1949; Christensen, 2009). This has led to several novel vaccination
procedures used in commercial broiler hatcheries which stimulate the chick’s immune
system early in chick development; these procedures include chick spray cabinets and in
ovo, or in egg, vaccinations (Sharma et al., 1984; Peterson, 1984; Johnston Jr., 2005). The
primary objective of vaccination in the hatchery is to stimulate the adaptive immune
system to develop immunological memory and promote competence against pathogens
present in a poultry house prior to the chick ever encountering them (Gildersleeve et al.,
1993; Schijns et al., 2014). Spray cabinets apply a uniform, fine mist of a viral or
bacterial vaccine that enters the chick’s body through inhalation, ocular membranes or
pecking off other chicks’ fluff (Peterson, 1984; Johnston Jr., 2005). In ovo vaccination is
an injection of a vaccine into the amniotic fluid of the embryo on d 18 of incubation
(Sharma et al., 1984). Although initial concerns existed towards the harm that puncturing
the egg may pose for the survivability of the embryo, it is determined that in ovo
vaccination is an extremely effective procedure when coupled with proper hatchery
hygiene (Johnston, 1997).

In ovo injection of probiotics
Upon the development and perfection of in ovo technology, much of the poultry
industry has transitioned to this method for early immune system stimulation in an
embryo (Gildersleeve et al., 1993; Schijns et al., 2014). The efficacy of in ovo technology
has led many researchers to study the applicability of the in ovo injection of probiotic
species (Haghighi et al., 2006; Maiorano et al., 2012; Oliveira et al., 2014; Slawińska et
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al., 2014; Ploweic et al., 2015; Pruszynska-Oszmalek et al., 2015; Pender et al., 2017;
Teague et al., 2017; Triplett et al., 2017). The goal of the in ovo probiotic injection is to
stimulate the development of the chick’s immune system through altering gastrointestinal
microbiome in a beneficial manner (Dibner et al., 1998; Roto et al., 2016). This would
then provide the chick with enhanced immunophysiological competence prior to hatching
(Dibner et al., 1998; Roto et al., 2016). The primary concern with injecting a bacteria
cocktail into a fertile broiler egg is that the probiotic cocktail will negatively affect the
embryo’s ability to hatch, cause contamination within the egg and negatively influence
the chick’s ability to perform upon hatch.
The oral consumption of probiotics has been proven to stimulate the immune
system of its host (Kabir et al., 2004; Delcenserie et al., 2008; Neu, 2007; Lin et al.,
2009; Salah et al., 2012; Hassanpour et al., 2013; Plaza-Díaz et al., 2018). Previous
studies noted the immunomodulatory effects that probiotics appear to have on children
(Lin et al., 2009; Underwood, 2016). Lin et al. (2009) observed the potential for regular
consumption of lactic acid producing probiotics in reducing viral and bacterial diseaserelated pediatric visits in preschool-aged children. In poultry, it was determined that a
commercial synbiotic formulation increased antibody titers in blood serum of birds when
compared to a control treatment throughout a grow-out period (Hassanpour et al., 2013).
Similarly, the consumption of lactic acid-producing bacteria, such as Lactobacillus spp.
and Pediococcus spp., in poultry exhibits modulation of the immune system through
upregulating anti-inflammatory cytokines such as IL-10 (Salah et al., 2012).
The manual injection of prebiotics and synbiotics have observed downregulation
in several pro-inflammatory and anti-inflammatory cytokines in the cecal tonsils of
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chicks (Sławinska et al., 2014; Płowiec et al., 2015). It is hypothesized that through
regulating the microbiota of the chicks prior to hatch, the birds do not exhibit extreme
cases of inflammation during the grow-out (Sławinska et al., 2014; Płowiec et al., 2015;
Pender et al., 2017). This is evident from a study by Castañeda et al. (2019), who
observed that the in ovo injection of E. coli into the amnion of the egg on day 18 of
incubation yielded elevated levels of the bacteria in tissues such as the bursa of Fabricius,
spleen and intestinal tissues by day 21. The injection of bacteria prior to hatch allows for
rapid colonization in the gastrointestinal tract of the chicks (Castañeda et al., 2019).
Previous studies with manual inoculation procedures have found that the injection
of certain probiotic species is capable of being injected into eggs without negatively
influencing hatch (Haghighi et al., 2006; Maiorano et al., 2012; Oliveira et al., 2014;
Pender et al., 2017; Teague et al., 2017; Triplett et al., 2017). Concurrently, the injection
of probiotics (such as Bacillus subtilis and Enterococcus faecium) may be capable of
reducing pathogens, such as Salmonella Enteritidis, within the gastrointestinal tract
(Oliveira et al., 2014). Lactic acid producing bacteria appear to be especially effective
probiotics for in ovo injection (Haghighi et al., 2006; Oliveira et al., 2014; Sławińska et
al., 2014; Płoweic et al., 2015; Pruszynska-Oszmalek et al., 2015; Pender et al., 2017;
Teague et al., 2017; Triplett et al., 2017). It is necessary to note that not all probiotic
species are compatible with in ovo procedures; Triplett et al. (2018) observed a
significantly negative effect on hatchability when a subspecies of Bacillus subtilis was in
ovo injected on d 18 of incubation. It is possible that some probiotics may be toxic to the
developing embryo due to the bacteriocins that they secrete into their external
environment (Gendron and Baines, 1987; Lai et al., 2012; Triplett et al., 2018).
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A drawback to many of these in ovo studies is that they conducted manual
injection procedures that injected high volumes of diluent into the egg when compared to
the industry standards for in ovo vaccination (Haghighi et al., 2006; Maiorano et al.,
2012; Oliveira et al., 2014; Pender et al., 2017; Teague et al., 2017). Limited data exists
on the applicability of in ovo probiotic injections using commercial in ovo technology. In
addition, many studies injected a probiotic cocktail rather than analyzing the impact of
individual probiotic species on chick development and immune system stimulation when
injected in ovo (Haghighi et al., 2006; Maiorano et al., 2012; Oliveira et al., 2014; Pender
et al., 2017; Teague et al., 2017). Therefore, further research is necessary to understand
the commercial applicability for the in ovo injection of individual probiotic species and
their combinations as well as how those probiotics influence hatchability, live
performance, and immune system development post-hatch.
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THE POTENTIAL FOR INOCULATING LACTOBACILLUS ANIMALIS AND
ENTEROCOCCUS FAECIUM ALONE OR IN COMBINATION USING
COMMERCIAL IN OVO TECHNOLOGY WITHOUT NEGATIVELY
IMPACTING HATCH AND POST-HATCH PERFORMANCE
Abstract
The poultry industry has recently undergone transitions into antibiotic free
production, and viable antibiotic alternatives, such as probiotics, are necessary. Through
in ovo probiotic inoculation, beneficial microflora development in the gastrointestinal
tract may occur prior to hatch without negatively impacting chick performance.
Therefore, the objective of the present study was to observe the impacts of the injection
of probiotic bacteria individually or combined into fertile broiler hatching eggs on hatch
and live performance characteristics. A total of 2,080 fertile broiler hatching eggs were
obtained from a commercial source. On d 18 of incubation, 4 in ovo injected treatments
were applied: 1.) Marek's Disease (HVT) vaccination, 2.) L. animalis (~106 cfu/50μL),
3.) E. faecium (~106 cfu/50μL), and 4.) L. animalis + E. faecium (~106 cfu & ~106
cfu/50μL each). On day of hatch, hatchability and hatch residue data were recorded. A
portion of male chicks from each treatment were placed in a grow-out facility for a 21 d
grow-out (18 chicks/pen ×10 pens/treatment = 720 male chicks) with a corn and soy bean
meal-based diet without antibiotics or antibiotic alternatives. Performance data and
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gastrointestinal samples were collected on d 0, 7, 14, and 21. Results indicated no
differences in all hatch parameters between treatments (P>0.05) except for % pipped,
where the L. animalis treatment had lower % pipped eggs compared to the HVT control
and E. faecium treatments (P=0.04). No differences were observed in body weight gain or
mortality (P>0.05). Probiotic treatments altered gastrointentional tissue length, weight,
and pH. This resulted in all in ovo injected probiotic treatments increasing FCR from d 714 as compared to the control (P=0.01). Differences in FCR were not observed in any
other week of data collection (d 0-7, 14-21, or 0-21; P>0.05). Although probiotics altered
live performance from d 7-14, these data suggest that in ovo inoculations of L. animalis
and E. faecium in combination are viable probiotic administration practices that
potentially improve hatch characteristics and gastrointestinal tract development.
Introduction
Probiotic applications in the poultry industry have grown in popularity in recent
years Due to extensive research, these studies observed improvements to broiler
performance, modulation of the immune system, and reduction in pathogens within the
gastrointestinal tract (Haghighi et al., 2006; Kabir, 2009; Pender, 2017). Commercially,
probiotics have the potential to prevent gastrointestinal diseases and promote the
colonization of beneficial bacteria within the gut. This colonization by probiotic products,
referred to as competitive exclusion, promotes the presence of beneficial bacteria in the
gastrointestinal tract thus preventing or reducing the presence of pathogenic bacteria.
Probiotic applications have been proven to alter the intestinal microflora which can, in
turn, elicit an immune response (Kabir, 2009; Pender, 2017). It has been observed that the
introduction of probiotics to chicks immediately after hatch has stimulated the production
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of natural antibodies, stimulated immune-related gene expression and reduced pathogen
presence within the gastrointestinal tract (Haghighi et al., 2006; Oliveira et al., 2014;
Slawińska et al., 2014; Płoweic et al., 2015).
There are many applied species of probiotics, including Lactobacillus animalis
and Enterococcus faecium. Lactobacillus spp. are gram positive, non-spore forming cocci
that secrete lactic acid into their external environment (Tannock, 1992). Previous studies
have found that lactic acid production by Lactobacillus spp. regulates environmental pH
to create an environment incompatible with many pathogenic bacteria species (Hutkins
and Nannen, 1993). Additionally, Lactobacillus spp. are noted for high adhesion to the
epithelial lining of the gastrointestinal tract (Tannock, 1992; Ehrmann et al., 2002;
Barrangou et al., 2012). In broilers, large populations of Lactobacillus spp. have been
identified in the duodenum, jejunum and ileum of the small intestines (Lu et al., 2003).
Enterococcus spp. are gram positive, non-spore forming cocci that produce lactic acid
(Tannock, 1992). Enterococci have also been found to secrete bacteriocins capable of
inhibiting microbial activity in the bacteria surrounding it (Tannock, 1992; Araujo and
Ferreira, 2013; Ness et al., 2014). Enterococcins, or bacteriocins secreted by
Enterococcus spp., include gelatinase, cytolysin and hyaluronidase; all of these
enterococcins play an integral role in degrading cell walls (Franz et al., 2007).
Enterococcus species have been previously identified in the ileum of the small intestines
of broiler chickens (Lu et al., 2003).
Presently, probiotics are mostly utilized through oral consumption in the poultry
industry, and this application method has observed improvements in growth performance
and gastrointestinal tract morphology (Yeo and Kim, 1997; Awad et al., 2009; Jeong and
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Kim, 2014; Bai et al., 2017). However, there are limitations with using probiotics as feed
additives. Fuller proposes that the avian species obtains its microflora from the nest it
hatches in; however, a broiler chick can be exposed to pathogenic bacteria upon hatch
without contacting beneficial bacteria commonly found in the nest prior to placement in a
house (1989). This modern method of animal rearing may be hindering the natural
development of the chick’s microflora (Fuller, 1989). In the commercial hatchery, many
pathogenic bacteria inhabit contact surfaces and the air which may potentially impact
chick health (Kim and Kim, 2010). Therefore, a new method of early probiotic delivery
through the use of commercial in ovo technology may provide a preliminary step towards
the chick establishing a healthy microflora before hatch, thereby reducing the impact
environmental pathogens have on the growth potential of the chick. To effectively utilize
this technology, research is necessary to determine the combinations of probiotic bacteria
species required to properly develop the gastrointestinal microflora.
Previous studies indicate that in ovo probiotic injections may improve flock health
(Cox et al., 1992; Meijerhof and Hulet, 1997; Oliveira et al., 2014; Triplett et al., 2018);
however, it is necessary to evaluate the effects that different probiotic species have on
hatchability, post-hatch live performance, and chick health. Although many experiments
have studied the in ovo inoculation of probiotics, these studies have small experimental
units, inoculate eggs manually, and utilize methodologies inapplicable in an industry
setting (Oliveira et al., 2014; Teague et al., 2017; Pender et al., 2017). This study
evaluates the in ovo injection of Enterococcus faecium and Lactobacillus animalis,
individually and in combination, using commercial Inovoject® technology. Both probiotic
cultures have been commonly observed as commensal bacteria within the crop, gizzard,
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duodenum, jejunum and ileum of birds (Wang et al., 2014; Ranjitkar et al., 2016).
Therefore, this study observed the effects of an in ovo injected probiotic combination on
performance parameters such as hatch of transfer, chick weight, gastrointestinal tissue
(GIT) weights, GIT lengths, GIT pH, feed conversion and body weight gain during the
first 21 days of growth.
Materials and Methods
In vitro Analysis of Bacterial Compatibility between L. animalis and E. faecium
Cultures
Before determining the compatibility of the two cultures, growth at 12 and 24 h of
incubation at 37˚C in selective media was measured for each probiotic bacteria
individually. For L. animalis, the culture was grown anaerobically in De Man, Rogosa
and Sharpe Broth (MRS; Millipore Sigma, St. Louis, MO) at 37˚C and spread on MRS
agar plates. For E. faecium, the culture was grown aerobically in Tryptic Soy Broth
(TSB; Millipore Sigma, St. Louis, MO) at 37˚C and spread on Bile Esculin agar (BEA;
Millipore Sigma, St. Louis, MO) plates. Desirable incubation time where growth reached
at least 106 cfu/mL for each culture was determined to be 12 h. In all in vitro procedures,
standard plate count procedures were followed. Plates were counted when colony growth
for a 10-fold dilution was within the range of 30 to 300 colonies per plate. All cultures
were plated and grown in duplicate, with average cfu/mL calculated as an average of the
duplicated plates.
After a bacteria growth curve was defined for each culture, the compatibility of L.
animalis and E. faecium when grown in the same environment was assessed. To
accomplish this, 1 mL from a 10 mL L. animalis stock culture that was incubated
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anaerobically in MRS broth for 24 h at 37˚C and 1 mL of E. faecium from a 10 mL stock
culture incubated aerobically in TSB for 24 h at 37˚C were inoculated into 8 mL of fresh
TSB. Two separate combination cultures containing the same amount of each inoculum
were created (two tubes containing 10 mL of TSB broth inoculated with L. animalis and
E. faecium). The combined probiotic bacteria culture, containing 1 mL E. faecium culture
and 1 mL L. animalis culture, was incubated for 12 h at 37˚C. One tube was incubated
aerobically for 12 h at 37˚C and the other was incubated anaerobically for 12 h at 37˚C.
After the 12 hour incubation period, a 10-fold serial dilution was conducted from the
incubated cultures. From each tube, the combined culture was spread on BEA and MRS
agar plates and incubated for 24 hours at 37˚C, where both agar types were grown in
aerobic and anaerobic conditions. Aerobically, E. faecium achieved 106 cfu/mL on BEA
agar. Anaerobically, L. animalis achieved 106 cfu/mL on MRS agar. After determining
the growth curves for the individual cultures and determining the compatibility of the
cultures when grown in the same environment, it was determined that both probiotic
types can coexist compatibly and yield a 106 cfu/mL concentration in their respective
environments aerobic and anaerobic environments, therefore the experiment proceeded to
the in vivo trial.
Preparation of the Applied Treatments
The applied treatments are as follows: 1.) Marek's Disease (HVT) vaccination
(control), 2.) L. animalis (~106 cfu/50μL) + HVT vaccination, 3.) E. faecium (~106
cfu/50μL) + HVT vaccination, and 4.) a combination of L. animalis and E. faecium (~106
cfu & ~106 cfu/50μL, respectively) + HVT vaccination. Treatments were prepared by
incubating L. animalis anaerobically and E. faecium aerobically in their respective broths
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(MRS and TSB, respectively) for 12 h at 37˚C the day prior to injection. Enough
inoculated broth was prepared of each probiotic bacteria to ensure the injection of at least
106 cfu/50 µl in ovo injection.
The amount of bacteria culture needed was calculated in reference to the 800 mL
sterile diluent bag (Merial Select, Inc., Gainesville, GA) used during the egg injection
process. In a 800 mL diluent bag, it was calculated that an individual injection volume of
50 µl yields 16,000 total injections. From the growth curve conducted previously, the
target growth for the bacteria culture after 12 hours of incubation is 106 cfu/mL.
Therefore, each vaccination would have a bacteria concentration of at least 1.0 × 106
cfu/mL. Under this presumption, the total amount of bacterial culture needed for the 800
mL diluent is 1.6 × 1010 cfu/mL (16,000 injections × 1.0 × 106 cfu/50 µL injection = 1.6
× 1010 cfu/800 mL). The total inoculated broth necessary to achieve a 106 cfu/50 µL
injection was calculated by dividing the bacteria concentration needed for injection by the
determined growth curve. For L. animalis, the average growth at 12 hours was 6.0 × 107
cfu/mL. Therefore, 266.7 mL of inoculated MRS broth was necessary for the L. animalis
treatment (1.6 × 1010 cfu/mL / 6.0 × 107 cfu/mL). For E. faecium, the average growth at
12 hours was 5.7 × 108 cfu/mL. Therefore, 28.1 mL of inoculated TSB was necessary for
the E. faecium treatment (1.6 × 1010 cfu/mL / 5.7 × 108 cfu/mL). Two sets of each culture
volume were inoculated, where one culture volume was designated for the single
probiotic treatment and the other volume was designated for the combination treatment.
On the morning of the in ovo probiotic injection day, the probiotic cultures were
added to the diluent bag after 12 h incubation at 37˚C. To do this, all tubes of cultures
were centrifuged at 4000 rpm at 4 ˚C for 10 minutes to obtain a pellet. After
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centrifugation, all broth is removed from the formed pellet. Using a sterile needle and
syringe, 1 mL diluent is drawn from the diluent bag and added to the pellet for
reconstitution. The reconstituted pellet is then added to its respective diluent bag. One
sterile diluent bag was designated for each treatment (4 diluent bags, total). Standard
HVT vaccine (4,000 doses/800 mL; Merial Select, Inc., Gainesville, GA) was added to
the each diluent bag, with sterile needles and syringes changed between treatments.
Inoculated diluent bags were stored at 4 ˚C until use.
Egg Incubation
A total of 2,080 fertile Ross 708 broiler hatching eggs from a 44 week old broilerbreeder flock were purchased from a commercial hatchery. Eggs were stored for 3 d at
21˚C until setting. Eggs were assessed for cracked or misshaped shells and individually
labelled by egg number, flat, and treatment where 18 flats (~ 30 eggs per flat; 520 eggs
total per treatment) were assigned to each treatment. To set eggs for incubation, flats
were arranged in 2 NatureForm® incubator units (NatureForm Hatchery Technologies,
Jacksonville, FL) where each treatment was equally represented in each unit. Incubator
temperature was set at 37.5°C, and relative humidity was set at 55.0%. On d 10, all eggs
were candled to identify and remove infertile, cracked, and contaminated eggs to ensure
that only fertilized eggs were to be injected. On d 18, 4 treatments were applied using
commercial Inovoject® equipment (Zoetis, Parsippany, NJ), eggs were transferred to
hatching baskets, and set into 1 of 12 Georgia Quail Farm® hatcher units (3 GQF
hatchers/treatment; Georgia Quail Farm, Savannah, GA). Each GQF unit contained 170
eggs. Incubator and hatcher disinfection was completed using a 10% Lysol solution.

61

Injection Procedure
On d 18 of incubation, commercial Inovoject® technology was utilized to apply
treatments to the developing eggs. Embryo staging was conducted during the injection
process where 1 egg was collected from 20 different flats through out the 2 NatureForm®
incubator units (5 eggs/treatment, each belonging to a different flat in each treatment; 20
eggs total) for an analysis of embryo development to ensure that the injected eggs were at
the appropriate stage of embryonic development. All other eggs proceeded to receive
their respective in ovo probiotic treatment. However, the selected eggs for embryo
staging (20 eggs total) were injected with 50 µl Coomassie blue dye solution (Thermo
Fisher Scientific, Waltham, MA) and immediately euthanized via CO2 asphyxiation. For
the remaining eggs, the treatments applied are the same as those listed in “Preparation of
the Applied Treatments”. Every treatment was prepared in 800 mL of sterile diluent prior
to injection (Merial Select Inc., Gainesville, GA). One flat was injected at a time, with all
eggs in the flat injected at once. Immediately after injection, eggs were placed in the
hatcher unit. A sanitation cycle recommended by Zoetis was completed between each
treatment, and microbial samples were collected on Tryptic Soy agar (TSA; Millipore
Sigma, St. Louis, MO) after each sanitation cycle to ensure that no contamination was
occurring within the in ovo equipment. Eggs were set in a manner to prevent
contamination between treatments: each treatment utilized 3 GQF hatchers (12 GQFs
total).
Hatch Procedure
On day of hatch, hatched chicks were counted, weighed, and sexed by wing
feather sexing (“Ross Broiler Management Manual”, 2009). Hatch residue analysis was
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conducted where unhatched eggs were counted and classified as early dead, mid dead,
late dead, infertile, contaminated, or cracked according to Aviagen egg break-out
guidelines (“How to… Break Out and Analyse Hatch Debris,” 2017). Male chicks from
the hatch were placed in pens of 18 chicks/pen according to treatment (10 pens/treatment)
in a grow-out facility at a stocking density of 0.20 m2/chick. Research pens in the house
were arranged to prevent cross contamination, where no pen had contact with the other
pens around it.
Grow-out and Sampling
A 21 d grow-out was carried out after hatch on used, windrowed litter from a
commercial broiler house. An industry standard basal diet which met Ross 708 nutrient
guidelines in crumble form was provided to birds in the starter (d 0-14) and grower (d 1421) phases. The starter and grower diets were crumble diets consisting of corn, soy bean
meal and poultry fat based on Ross 708 guidelines and did not contain antibiotics,
antibiotic alternatives or anticoccidials (“Ross 708 Nutrition Specifications”, 2014). Feed
and water were supplied ad libitum. Chick mortality, body weight gain, and feed
consumption were obtained on d 0, 7, 14, and 21 of the grow-out. Gastrointestinal tissue
samples were collected on d 0, 7, 14, and 21 of the grow-out (10 birds/treatment for each
sampling day). The pH of the crop, gizzard, duodenum, jejunum, ileum, and ceca were
measured with digesta contents on d 7, 14, and 21. Tissue weights with digesta for the
duodenum, jejunum, ileum, ceca, bursa, and spleen were sampled. All animals in this trial
were treated in compliance with the Guide for the Care and Uses of Agriculture Animals
in Research and Teaching (Federation of Animal Science Societies, 2010) and the
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Mississippi State University Institutional Animal Care and Use Committee (IACUC
Animal Welfare Assurance #A3160-01).
Statistical Analysis
All data were analyzed using SAS v.9.4 (SAS Institute, Cary, NC). Incubation
data were analyzed using a completely randomized design. The experimental unit was
GQF hatcher unit (3 GQFs/treatment). Live performance data were analyzed using a
randomized complete block design with a split plot over time. The experimental unit was
pen (10 pens/treatment). Means were separated using Fisher’s Protected LSD and
differences were considered significant when P ≤ 0.05 (Steel and Torrie, 1980).
Results
Verification of Injection Procedures
Embryo staging conducted after the injection procedure on d 18 of incubation
determined that the injection procedure was accurate. Embryos were at d 18 of
development with 3 lobes in the yok sac and the intestines were enclosed in the body
cavity. Also, the coomassie blue dye applied for embryo staging was on the feathers of
the embryo, which confirmed that the injection was in the amnion. Probiotic
concentrations for each treatment were as follows: no bacterial growth in the diluent
treatment, 3.1 × 109 cfu/50 μL of L. animalis and 0 cfu/50 μL of E. faecium in the L.
animalis treatment, 0 cfu/50μL of L. animalis and 5.4 × 106 cfu/50μL of E. faecium in the
E. faecium treatment, and 3.0 × 107 cfu/50 μL of L. animalis and 4.0 × 106 cfu/50 μL of
E. faecium for the combination treatment.
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Hatch Parameters
No difference in hatch of transfer was observed between the L. animalis, the
combination, the HVT control, and E. faecium treatments (P=0.65; Table 3.1). During
the hatch residue analysis, no significant differences were found in percent late dead,
cracked, contaminated or cull eggs (P≥0.05; Table 3.1). There was a significant
difference in percent pipped eggs between treatments (P=0.039; Table 3.1) where eggs in
the HVT control, E. faecium, and the combination treatments were not different from
each other; however, they were significantly greater than the eggs of the L. animalis
treatment (Table 3.1). There were no significant differences in average chick weight
between the applied treatments (P=0.39; Table 3.1).
Live Performance Parameters
For all phases of the 21 d grow-out, there were no significant differences in
mortality or live weight gain between all treatments (P>0.05; Table 3.2). There was a
difference in feed conversion ratio (FCR) only in the d 7-14 phase, where the chicks in
the E. faecium and the combination treatments yielded greater FCR than the chicks in the
HVT control treatment. However, no treatments were significantly different from the L.
animalis treatment (P=0.01; Table 3.2). Unlike the d 7-14 phase, no significant
differences in FCR were observed among treatments on d 0-7, d 14-21, or d 0-21 phases
(P>0.05; Table 3.2).
Tissue Weight Relative to Live Body Weight
Treatment by day interactions for tissue weight relative to body weight were
observed in the jejunum, ileum, and ceca (P=0.0001, 0.002, and 0.007, respectively;
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Figure 3.1). No significant differences between treatments were observed in the jejunum
on d 0 or in the ileum on d 0 and 7. However, jejunum and ileum weights were
significantly greater in all probiotic treatments when compared to the control treatment
on d 14. Similarly, chicks in ovo injected with E. faecium or the combination both
observed greater jejunum and ileum weights on d 21. For the ceca, chicks in ovo injected
with L. animalis obtained greater ceca weights relative to body weight on d 0. On d 7,
chicks in the E. faecium treatment observed greater ceca weights when compared to
chicks of the control and combination treatments. No difference in ceca weights among
treatments was observed after d 7.
Significant treatment by day interactions were also observed in bursa weight
relative to body weight where chicks in ovo injected with E. faecium or the combination
both obtained smaller bursa weights relative to body weight on d 7 when compared to
those injected with the HVT control. By d 21, chicks in ovo injected with E. faecium or
the combination treatments both yielded significantly larger average bursa weights when
compared to the in ovo injection of L. animalis (P=0.02; Figure 3.2).
Tissue Length relative to Small Intestines Length
There were significant treatment by day interactions for tissue length relative to
total small intestines length observed in the duodenum, ileum and ceca (P=0.03, 0.04 and
0.007, respectively; Figure 3.3). Although no differences were observed between
treatments on d 0 or d 14 for duodenum length, chicks in ovo injected with L. animalis
obtained significantly longer duodenum lengths on d 7 when compared to all treatments
on that day. Concurrently, the chicks in ovo injected with the combination treatment
observed shorter relative duodenum lengths when compared to those injected with L.
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animalis or E. faecium on d 21. Unlike the duodenum, the in ovo injection E. faecium or
the combination both yielded significantly longer tissues in the ileum when compared to
the birds injected with the HVT control on d 0. On d 7, the relative ileum lengths in E.
faecium and the combination treatments were significantly longer than L. animalis
treatments. Similar to the relative duodenum length, no differences in relative ileum
lengths were observed on d 14. Unlike the duodenum, the in ovo injection of the
combination yielded chicks with significantly longer ileums when compared to those who
received the E. faecium injection on d 21. However, ileum lengths in the E. faecium and
combination treatments on d 21 were not different from L. animalis or the control relative
ileum lengths on d 21. In the ceca, the birds from the combination yielded longer relative
ceca tissues when compared to the HVT control and L. animalis treatments. However, no
other treatment by day interactions were observed in the ceca on d 7, 14 or 21.
Tissue pH
Treatment by day interactions were also observed in crop, gizzard, duodenum and
jejunum pH (P=0.001, 0.008, 0.05 and 0.05, respectively; Figure 3.4). On d 7, no
treatment differences were observed in the gizzard, duodenum or jejunum. However, it
was observed that chicks in ovo injected with L. animalis obtained lower pH in the crop
when compared to chicks in ovo injected with E. faecium and combination treatments.
The crop and gizzard also observed decreased pH levels in the chicks in the HVT control
treatment when compared to the birds of all probiotic treatments on d 14 and d 21. Also,
the gizzard pH on d 14 in chicks in ovo injected with the combination was not different
from those of the L. animalis treatment but significantly lower than chicks in the E.
faecium treatment. However, the HVT control treatment yielded a significantly lower pH
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in the gizzard on d 14 when compared to all probiotic treatments. The pH of the
duodenum in birds who received the combination treatment on d 14 was greater than
those of the HVT control treatment, but they were not different from the duodenum pH of
the L. animalis or E. faecium treatments. The pH of the jejunum on d 14 was greater for
birds who were in ovo injected with the combination treatment when compared to all
other treatments. On d 21, no significant differences in tissue pH were observed in the
gizzard, duodenum and jejunum. However, chicks in ovo injected with L. animalis or the
combination had a significantly elevated pH in the crop on d 21 when compared to the
control HVT injection. Crop pH in the L. animalis or combination treatments were not
different from E. faecium on d 21.
Discussion
Hatch Parameters
This experiment utilized commercial Inovoject® equipment to inject two different
probiotic species, L. animalis and E. faecium, individually and in combination into fertile
broiler hatching eggs. Other companies have created in ovo technology similar to
Inovoject®, and this study provides insight into the applicability of in ovo probiotic
injections using commercially available technology. Methodology such as this provides
an industry perspective on the application of a probiotic during the standard vaccination
of a vaccine. Although in ovo probiotic studies have been conducted, many of these
studies consist of manual injection procedures that inject greater volumes of a diluent
than the volume applied with commercial in ovo injection equipment (Oliveira et al.,
2014; Madej et al., 2015; Madej et al., 2016; Pender et al., 2017). Even so, previous
research on in ovo probiotic inoculation has found that probiotics can have positive and
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negative impacts on chick performance while stimulating the immune system (Sławińska
et al., 2014; Madej et al., 2015; Płoweic et al., 2015; Madej et al., 2016; Pender et al.,
2017; Triplett et al., 2018).
Concerns do exist when injecting beneficial supplements, such as probiotics, into
fertile broiler hatching eggs on d 18 of incubation. It has been found that the in ovo
injections of probiotics and vaccines into fertile hatching eggs may have a negative
impact on hatchability, but these results are dependent on the probiotic type and injection
location (Cox et al., 1992; Meijerhof and Hulet, 1997; Oliveira et al., 2014; Triplett et al.,
2018). This negative impact may exist due to the injection process: puncturing the
cuticle, shell, and membranes of an egg. This may then lead to pathogenic bacteria in the
external environment gaining direct access to the embryo. Sanitary conditions, such as
needle sterilization, are necessary to ensure that chicken embryos are not negatively
affected by the inoculation process (Johnston et al., 1997).
In the present study, no negative impacts were evident from the injection
procedure. It was observed that the L. animalis treatment significantly reduced
percentage pipped eggs when compared to the control treatment. This indicates that it is
possible to inject L. animalis into the amnion of an embryo on d 18 of embryonic
development with potential to improve hatch performance. Previous research studying
the impact of probiotic in ovo injections did not observe similar results (Oliveira et al.,
2014; Pender et al., 2017; Teague et al., 2017; Triplett et al., 2018). Probiotic species and
the concentration being injected (Triplett et al., 2018) as well as the volume of the
injection and methods of injection (Oliveira et al., 2014; Pender et al., 2017; Teague et
al., 2017) all potentially impact hatch performance. Because beneficial bacteria species
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have differing primary modes of action, the injection of one bacteria species into a fertile
hatching egg may induce different biological responses in the chick when compared to
another probiotic bacteria species.
Some of these biological responses may be linked to bacteriocin production by
some probiotic species. Bacteriocins are bacteriocidal proteins commonly secreted by
lactic acid producing bacteria species such as Lactobacillus and Enterococcus (Cintas et
al., 2001). Lactic acid and bacteriocin production by many probiotic species are key
components of pathogen reduction in the gastrointestinal tract of their host (Guerra et al.,
2006; Mountzouris et al., 2007; Aliakbarpour et al., 2012). Through their differing modes
of action, probiotics have been shown to improve performance for in-feed applications
where it is introduced into the gastrointestinal tract of a maturing chick (Jeong and Kim,
2014; Bai et al., 2018). Through the supplementation of probiotics in ovo, prior to the
chick ever contacting pathogenic bacteria in the external environment, it may be possible
to initiate early colonization of beneficial bacteria species in the gut to prevent pathogen
colonization and improve chick performance upon hatch (Ballou et al., 2016). However,
the same bacteria species injected in ovo may not exhibit synergistic characteristics with
the embryo and impair hatch performance (Cox et al., 1992; Meijerhof and Hulet, 1997;
Jeong and Kim, 2014; Bai et al., 2018; Triplett et al., 2018).
For example, previous studies have observed the possible hazards that probiotic
administration may pose for humans who are immunocompromised (Oggioni et al., 1998;
Hassan et al., 2018). In a meta-analysis of cancer patients who consumed probiotic
supplements during their treatment, a safety analysis noted 5 out of the 25 studies yielded
infections in patients which were linked to their probiotic consumption (Hassan et al.,
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2018). Concurrently, there are beneficial impacts that probiotic supplementation has on
patients, which include diarrhea reduction and fever reduction in individuals who are in
an immunocompromised state (Ceccarelli et al., 2017; Hassan et al., 2018). Due to the
potential for probiotics to act pathogenically within an immunocompromised host, it is
possible that chicken embryos, whose immune systems do not achieve maturations until
weeks after hatch, may be negatively influenced by in ovo probiotic supplementation
post-hatch (Dibner et al., 1998).
Even so, previous research that compared the in ovo application of different
individual probiotic species has found that the in ovo injection of Lactobacillus spp. does
not negatively affect hatchability (Triplett et al., 2018). A study by Triplett et al. (2018)
observed the possible impacts that lactic acid and bacteriocin producing bacteria have on
the developing embryo when injected using Inovoject® equipment. It was observed that
the injection of Lactobacillus acidophilus or Bifidobacterium animalis using commercial
Inovoject® equipment did not positively or negatively affect hatch of fertilized eggs when
compared to the control (Triplett et al., 2018). However, a Bacillus subtilis species had a
significant negative impact on hatch of fertilized eggs when compared to the control
(Triplett et al., 2018). Previous research has found that Bacillus subtilis has the potential
to improve broiler performance when supplemented in the feed (Jeong and Kim, 2014;
Bai et al., 2018). Lactobacillus spp. and Bacillus spp. have differing modes of action that
may potentially impact the embryo differently when injected into the amnion.
Lactobacillus species have high epithelial adhesion capabilities and produces lactic acid
through fermentative processes, while Bacillus secretes lactate, acetoin, 2,3-butanediol,
acetate and ethanol through fermentative processes (Hutkins and Nannen, 1993;
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Nicholson, 2008; Lai et al., 2012; Shokryazdan et al., 2014). Although further studies are
necessary to understand the interaction between these metabolic fermentation products
and the broiler embryo, it has been found that 2,3-butanediol enhances natural killer cell
cytotoxicity which advances spontaneous abortion in mice species (Gendron and Baines,
1987; Lai et al., 2012). Similar natural killer cells have been observed in the developing
avian embryo (Jansen et al., 2010), which may have attributed to the high embryo
mortality found with the injection of Bacillus subtilis by Triplett et al. (2018).
The injection of L. animalis and E. faecium, probiotics with different
characteristics in vitro, into fertile broiler hatching eggs on d 18 of incubation did not
demonstrate any of the negative effects observed by Triplett et al. from bacteriocin or
lactic acid production (2018). This is important to note as it was found during the
verification of injection procedures that the L. animalis and the combination treatments
exhibited notably elevated L. animalis concentrations when compared to E. faecium
concentrations. This may be due to a high growth rate observed when the L. animalis
culture was grown in broth during treatment preparation. Even though L. animalis grew
more rigorously in the preparation of the treatments when compared to its growth when
formulating the growth curve, a bacterial concentration of 109 cfu/50 μL L. animalis
injected into fertile broiler hatching eggs yielded 0% contaminated eggs in the L.
animalis treatment. Also, a combined injection of L. animalis at 107 cfu/50 μL and E.
faecium at 106 cfu/50 μL did not impact any hatch residue or any of the hatch parameters
when compared to the HVT control treatment. This indicates that the injection of a live
probiotic bacteria culture did not negatively impact hatchability, even when the injected
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concentration was as high as 109 cfu/50 μL L. animalis in the L. animalis injected
treatment.
Other than percentage pipped eggs, the hatch parameters analyzed in the present
study yielded no significant differences due to treatment. These variables, including chick
weight, percent cracked, percent contaminated, or percent late dead eggs, indicate that the
in ovo injection of a probiotic combination including L. animalis and E. faecium does not
negatively impact on the developing embryo and its ability to hatch. In an analysis by
Johnston (1997), it was determined that the use of in ovo technology to administer the
Marek’s disease vaccine does not negatively impact many hatch parameters, such as posthatch chick mortality, when compared to post-hatch vaccination. In the present study, the
L. animalis treatment had a positive impact on the developing embryo where there were
significantly lower percentage pipped eggs when compared to the control. However, it is
important to note that the chicks in ovo injected with E. faecium or the combination
treatment were not significantly different from the HVT control treatment in hatchability
of transferred eggs or percentage pipped eggs.
Live Performance and Gastrointestinal Tissue Parameters
The lack of differences observed in many of the live performance parameters
between the HVT control and probiotic treatments further demonstrates the efficiency
and implications of using in ovo technology for probiotic supplementation. Similar results
were observed in an analysis conducted by Gildersleeve et al. (1993), where in ovo
vaccination of fertilized broiler hatching eggs and conventional post-hatch vaccination
methods were compared in a commercial setting. With no significant differences in early
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post-hatch mortality in the present study, neither the in ovo technology utilized nor the
probiotics introduced to the embryo negatively impacted chick mortality post-hatch.
A treatment effect for FCR was yielded during the d 7-14 phase in the present
study, where E. faecium and the combination treatments yielded an increased FCR in
comparison to those in the HVT control treatment. No other FCR treatment effects were
observed in the other growth phases (d 0-7, d 14-21 or d 0-21). The performance
difference on d 7-14 may be attributed to weight, length and pH differences found in the
gastrointestinal tissues among the probiotic treatments when compared to the HVT
control. Due to the observance of altered gastrointestinal parameters and an increased
FCR during grow-out in the d 7-14 phase, it is possible that the in ovo injection of
probiotics is capable of altering the physiological development of the chick’s
gastrointestinal tract during the first 21 days of life. Whether or not these alterations
caused by in ovo supplementations of L. animalis and/or E. faecium are beneficial over
the course of the entire grow-out is yet to be established.
Previous research in other organism models have found that the natural gut
microflora is capable of modulating the expression of genes associated with gut
epithelium development (Hooper et al., 2001; Lange et al., 2010). Similarly, a study by
Pruszynska-Oszmalek et al. discovered that the in ovo injection of probiotics or
synbiotics elevated amylase, hydrolase, and trypsin activity by the pancreas, which may
potentially improve bird performance (2015). Contradictively, a study with the in-feed
application of probiotics found that the supplementation decreased urease activity in
broiler chicks (Yeo and Kim, 1997). Although studies are continuing to investigate the
impact of probiotics on the digestive system, the interaction between the gastrointestinal
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microbiome and the functionality of the gastrointestinal tract is complex and not
completely understood in the broiler chicken (Yeo and Kim, 1997; Lu et al., 2003;
Pruszynska-Oszmalek et al., 2015; Ballou et al., 2016).
In the present study, the injected probiotic species, L. animalis and E. faecium,
may be capable of diversely influencing the gastrointestinal tract of its host (Hutkins and
Nannen, 1993; Franz et al., 2007; Shokryazdan et al., 2014). Other studies have observed
an increase in gut tissue weights when probiotics are supplemented in feed, which may be
the cause of altered gastrointestinal tissue weights observed in the present trial when
probiotics were injected in ovo (Awad et al., 2009). It was previously proposed that this
increase in tissue weight may be indicative of greater surface area in the small intestines
which may lead to increased nutrient and water absorption (Awad et al., 2009). However,
Coates et al. suggests that an increase in intestinal weight may be indicative of an
uncharacterized infection within the gut and therefore may lead to an increase in feed
intake (1955). This may be the case for the present study, as it was found that the
probiotic treatments had greater FCR along with greater jejunum and ileum weights when
compared to the control on d 14. Alternatively, Jin et al. (2000) observed that the
inclusion of Lactobacillus spp. in feed did not alter gastrointestinal tissue weights nor did
it negatively impact FCR. Similarly, Oliveira et al. (2014) yielded no significant weight
gain or feed conversion ratio differences between injected probiotic treatments and the
control even when challenged with Salmonella. This may suggest that the in ovo injection
of a probiotic combination different from E. faecium and L. animalis may be capable of
promoting efficient live performance through modulating the development of the
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gastrointestinal tissues. Moreover, further research is necessary to understand these
relationships in the future.
It is pertinent to address that treatment interactions were observed where L.
animalis reduced crop pH when compared to the E. faecium and combination treatments
on d 7. This may be due to its lactic acid production, although further research pertaining
to microbiome analysis is necessary to directly link in ovo probiotic supplementation to
the bacterial composition of the gut and tissue pH (Kashket, 1987; Hutkins and Nannen,
1993; Cintas et al., 2001). For instance, Ranjitkar et al. (2016) observed high levels of
bacteria belonging to the Lactobacillaceae family in the crop, gizzard and ileum, and
high levels of bacteria belonging to the Enterococcacae family in the ileum. In ovo
probiotic supplementation may be capable of manipulating these populations, but further
research is necessary to understand this interaction.
Therefore, this pH difference in the crop among probiotic treatments on d 7 may
be demonstrative of the embryo consuming the probiotic that was injected into the
amnion prior to hatch (Moran, 2007). However, the in ovo probiotic treatments were not
capable of maintaining a lower pH in the gastrointestinal tract when compared to the noninjected control, even on d 7. This may indicate that the injected probiotics do not have
high adherence to the epithelium of the gastrointestinal tract after injection and are
sloughed off within the first week of hatch. However, Marciňáková et al. (2010) tested
the survivability of an E. faecium strain isolated from chicken jejunum; in vitro, it was
observed that multiple isolated E. faecium strains were capable of surviving simulated
gastrointestinal conditions but exhibited low adhesion characteristics. The results
obtained by Marciňáková et al. (2010) may explain why the gastrointestinal pH in the
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present study where any of the tissues of the E. faecium treatment consistently exhibited a
higher pH than the control tissues.
Alternatively, Ehrmann et al. (2002) supplemented a one time inclusion of
Lactobacillus spp. in feed and was able to recover that species from the fecal matter of
ducks over a 28 day study. This may not have been observed in the present study, where
the L. animalis and combination treatments observed an elevated pH in the crop when
compared to the HVT control treatment by d 21. As previously stated, analysis of the
microbiome of gastrointestinal tract is necessary to directly understand the relationship
that the in ovo injection of probiotics may have on the development and maintenance of a
chick’s microbiome. It is expected that through in-feed probiotic applications coupled
with in ovo probiotic injections, higher levels of lactic-acid producing probiotics may be
maintained in the foregut for longer periods of time.
Bursa Weights
Along with gastrointestinal tissues, bursa weight relative to body weight appeared
to be influenced by the in ovo injection of the E. faecium and combination treatments.
Even though changes in bursa weight might indicate that the in ovo injection of E.
faecium and the combination induced an immune response early in the grow-out, these
differences may not be indicative of a stimulated immune system (Glick, 1963; Cazaban
et al., 2015; Fathi et al., 2017). In a study by Glick et al. (1963), reduced bursa weights in
Pekin ducks did not decrease the level of circulating leukocytes in the blood.
Additionally, Cazaban et al. (2015) observed high variations in bursa weights among
broilers as the birds aged. Therefore, further analyses of circulating blood leukocyte
counts, B-cell enumeration, antibody response, and immune cell expression in gut77

associated lymphoid tissues are necessary to gain a comprehensive understanding of
immune responses stimulated by individual probiotics and their combinations (Chrząstek
et al., 2011; Madej and Bednarcyzk, 2016).
Implications and Future Research
The results of this study indicate that individual probiotics with differing modes
of action can be injected into fertilized broiler hatching eggs simultaneously without
negatively impacting hatch and live performance. L. animalis may be more compatible
with the in ovo injection process due to its significant improvement in percent pipped
mortality. However, the present study only conducted a 21 d grow-out. Even though an
increase in FCR was yielded in the in ovo injected E. faecium and combination treatments
during the d 7-14 phase of the trial, a 49 d grow-out may observe positive differences in
broiler performance in the probiotic treatments because immune system maturation does
not occur until d 21 post-hatch (Dibner et al., 1998). Additionally, the differences in gut
morphology among treatments that occurred in the current study may not yield positive
performance differences until weeks later (Dibner et al., 1998).
Future studies using different probiotic bacteria in combination with L. animalis
may demonstrate improvements not only for hatch but also improvements in live
performance parameters. A more accurate analysis of gut microbiota is also necessary to
understand the amount of time that an in ovo injected probiotic can be maintained in the
gastrointestinal tract. Furthermore, research is also needed to understand synergistic
capabilities of in ovo injection and in-feed probiotic applications, which may alter
gastrointestinal pH levels during grow-out and reduce pathogen presence in the gut.
Differences in probiotic applications, whether in-feed or in ovo, and the formulation of
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those probiotics may impact the success of any probiotic supplementation with improving
bird performance, and the success of the probiotic program may rely on how those
formulations interact with the existing gut microflora. Therefore, a different probiotic
combination from the one proposed in the present study may have the potential to
decrease FCR during grow-out. Lastly, an analysis of immune response associated with
the injection of these different probiotic species and their combinations using Inovoject®
equipment is necessary to understand the impacts that the differing modes of action have
on the chick after hatch.
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Tables
Table 3.1

Effect of in ovo injected L. animalis, E. faecium, or their combination on
hatch parameters

Treatments

HVT
Control

L. animalis

E.
faecium

% hatch of transfer

93.37

94.62

93.24

93.52

1.09 0.6498

% late dead eggs

4.43

4.93

4.05

3.10

1.34 0.2309

% pipped eggs

1.98a

0b

1.58a

1.47a

1.50 0.0389

% cracked eggs

0.22

0

0.45

0

0.37 0.2175

% contaminated eggs

0

0

0.45

0.58

0.52 0.4635

% cull eggs

0

0

0

0

Combination SEM

.

P
value

.

Avg Chick Weight
46.2
45.9
46.2
45.4
3.60 0.3900
(g)
Different superscripts (a - b) indicate significant differences in the means of treatments,
where differences are considered significant at P ≤ 0.05. N = 3, where each replicate in
the treatment was a GQF hatcher unit (~170 eggs/GQF; 520 total eggs/treatment).
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Table 3.2

Effect of in ovo injected L. animalis, E. faecium, or their combination on live performance parameters for d 0-21
Phase

d 0-7

d 7-14

d 14-21

d 0-21

Parameter measured

HVT
Control

Live Weight Gain/Bird (kg)

0.09

0.10

0.09

0.09

0.03

0.8283

Feed Conversion Ratio

1.30

1.28

1.31

1.30

0.03

0.9639

Mortality

0.56

0.62

1.23

2.22

0.91

0.5030

Live Weight Gain/Bird (kg)

0.23

0.22

0.22

0.21

0.01

0.2114

Feed Conversion Ratio

1.29b

1.31ab

1.34a

1.35a

0.01

0.0096

Mortality

0.00

0.65

0.00

0.00

0.31

0.3913

Live Weight Gain/Bird (kg)

0.39

0.38

0.40

0.39

0.01

0.5091

Feed Conversion Ratio

1.42

1.47

1.42

1.47

0.03

0.4692

Mortality

0.63

0.67

0.67

0.71

0.64

0.8086

Live Weight Gain/Bird (kg)

0.72

0.70

0.71

0.69

0.02

0.6485

Feed Conversion Ratio

1.37

1.39

1.40

1.43

0.02

0.1558

L. animalis E. faecium Combination SEM P value

Mortality
1.11
1.23
1.85
2.78
1.32 0.7655
Different superscripts (a - b) indicate significance between treatments within the performance parameter, where differences are
considered significant at P≤ 0.05. N = 10, where each replicate in the treatment is a pen (18 birds/pen; 180 total birds/treatment).
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Figures

Figure 3.1

Treatment by day interaction for the impacts of in ovo injected L. animalis, E. faecium, or their combination on
gastrointestinal tissue and contents weight relative to live body weight over a 21 day grow-out (%)
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Figure 3.1 Notes
Treatment by day interactions were observed in the jejunum, ileum, and ceca for tissue
weight relative to live body weight. The HVT control injection is represented by the gray
shaded bar. The L. animalis injected probiotic treatment is represented by the white
shaded bar. The E. faecium injected probiotic treatment is represented by the striped bar.
The L. animlais + E. faecium combination injected probiotic treatment is represented by
the dotted bar. Tissue weight relative to total body weight (%) is on the y-axis. Tissue
sampled (jejunum, ileum, and ceca) and day of sampling (d 0, d 7, d 14, and d 21) are on
the x-axis. SEM and P values are located underneath each of their respective tissues.
Differences were considered significant at P ≤ 0.05, error bars for each tissue represent
the SEM for that tissue, and N = 10 (10 pens/treatment; one bird randomly sampled from
each pen on each sampling day). Although all tissues with a treatment by day interaction
for tissue weight relative to body weight are provided on the same figure, the analysis for
the treatment by day interaction is by individual tissues. Significant differences are noted
by alphabetical superscripts, where each change in a letter represents a significant
difference among treatments. Jejunum superscripts are a - e, ileum superscripts are a - g,
and ceca superscripts are a - h.
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Figure 3.2

Treatment by day interaction for the impacts of in ovo injected L. animalis,
E. faecium, or their combination on Bursa of Fabricius weight relative to
live body weight over a 21 day grow-out (%)

A treatment by day interaction was observed for Bursa of Fabricius weight relative to live
body weight. The HVT control injection is represented by the gray shaded bar. The L.
animalis injected probiotic treatment is represented by the white shaded bar. The E.
faecium injected probiotic treatment is represented by the striped bar. The L. animlais +
E. faecium combination injected probiotic treatment is represented by the dotted bar.
Bursa weight relative to total body weight (%) is on the y-axis, and day of grow-out (d 0,
d 7, d 14, and d 21) is on the x-axis. The SEM and P value is located in the bottom right
corner of the figure. Differences were considered significant at P ≤ 0.05, error bars
represent the SEM, and N = 10 (10 pens/treatment; one bird randomly sampled from each
pen on each sampling day). Significant differences are noted by alphabetical superscripts,
where each change in a letter represents a significant difference among treatments. The
superscripts for this figure include a - i.
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Figure 3.3

Treatment by day interaction for the impacts of in ovo injected L. animalis, E. faecium, or their combination on
gastrointestinal tissue length relative to total small intestines length over a 21 day grow-out (%)
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Figure 3.3 Notes
Treatment by day interactions were observed in the duodenum, ileum, and ceca for tissue
length relative to small intestines length. The HVT control injection is represented by the
gray shaded bar. The L. animalis injected probiotic treatment is represented by the white
shaded bar. The E. faecium injected probiotic treatment is represented by the striped bar.
The L. animlais + E. faecium combination injected probiotic treatment is represented by
the dotted bar. Tissue length relative to total small intestines length (%) is on the y-axis.
Tissue sampled (duodenum, ileum, and ceca) and day of sampling (d 0, d 7, d 14, and d
21) are on the x-axis. SEM and P values are located underneath each of their respective
tissues. Differences were considered significant at P ≤ 0.05, error bars for each tissue
represent the SEM for that tissue, and N = 10 (10 pens/treatment; one bird randomly
sampled from each pen on each sampling day). Although all tissues with a treatment by
day interaction for tissue length relative to small intestines length are provided on the
same figure, the analysis for the treatment by day interaction is by individual tissues.
Significant differences are noted by alphabetical superscripts, where each change in a
letter represents a significant difference among treatments. Duodenum superscripts are a e, ileum superscripts are a - g, and ceca superscripts are a - g.
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Figure 3.4

Treatment by day interaction for the impacts of in ovo injected L. animalis, E. faecium, or their combination on
gastrointestinal tissue pH over a 21 day grow-out (%)
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Figure 3. 4 Notes
Treatment by day interactions were observed in the crop, gizzard, duodenum, and
jejunum for tissue pH. The HVT control injection is represented by the gray shaded bar.
The L. animalis injected probiotic treatment is represented by the white shaded bar. The
E. faecium injected probiotic treatment is represented by the striped bar. The L. animlais
+ E. faecium combination injected probiotic treatment is represented by the dotted bar.
Tissue pH is on the y-axis. Tissue sampled (crop, gizzard, duodenum, and jejunum) and
day of sampling (d 7, d 14, and d 21) are on the x-axis. SEM and P values are located
underneath each of their respective tissues. Differences were considered significant at P ≤
0.05, error bars for each tissue represent the SEM for that tissue, and N = 10 (10
pens/treatment; one bird randomly sampled from each pen on each sampling day).
Although all tissues with a treatment by day interaction for tissue pH are provided on the
same figure, the analysis for the treatment by day interaction is by individual tissues.
Significant differences are noted by alphabetical superscripts, where each change in a
letter represents a significant difference among treatments. Crop superscripts are a - f,
gizzard superscripts are a - d, duodenum superscripts are a - e, and jejunum superscripts
are a - f.
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THE POTENTIAL FOR INOCULATING LACTOBACILLUS ANIMALIS AND
BACILLUS LICHENIFORMIS ALONE OR IN COMBINATION USING
COMMERCIAL IN OVO TECHNOLOGY AND ITS INFLUENCE ON
HATCHABILITY, LIVE PERFORMANCE, AND IMMUNE
RESPONSE
Abstract
Feed applications of probiotics, such as Lactobacillus animalis and Bacillus
licheniformis, have improved performance while stimulating the immune system of
poultry. However, immunological responses have not been confirmed when these
probiotics are injected in ovo. Therefore, the current objective determined if the in ovo
injection of the combination of L. animalis and B. licheniformis influence broiler immune
systems. Treatments were randomly applied to 2,880 fertile broiler hatching eggs on d 18
of incubation and included: Marek's Disease (HVT) vaccination, L. animalis (~106
cfu/50μL) + HVT, B. licheniformis (~106 cfu/50μL) + HVT, and L. animalis (106
cfu/50μL) + B. licheniformis (~106 cfu/50μL) + HVT. Hatch of transfer and hatch residue
data were collected. Following hatch, a 49 d grow out with a coccidiosis challenge on d
14 was performed. Immunological parameters (bursa follicle area, white blood cell
counts, and cytokine quantities) were collected on d 0, 21 and 28. There was no
difference in hatch of transfer (P=0.6), but B. licheniformis yielded fewer % late dead
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eggs when compared to the control (P=0.04). Although present, no differences were
observed in the incidence of coccidiosis-associated lesion scores among treatments
(P>0.05). However, L. animalis yielded an elevated FCR during d 14-28 (P=0.03). A
treatment interaction was observed for ileum weights among probiotic and control
treatments (P=0.03). For cytokine quantification, treatment interactions were observed. B.
licheniformis upregulated IL-6, IL-12-p40, and IL-16 on d 0, the combination
upregulated IL-21 on d 28, and B. licheniformis upregulated IL-10 on d 28 (P<0.05). A
treatment interaction in percent lymphocytes was observed where probiotic treatments
altered lymphocyte quantities over the first 28 d of life (P=0.005). These results indicate
that the in ovo injection of probiotic bacteria can alter immuno-physiological responses
post-hatch when birds are subsequently challenged with coccidiosis. This procedure has
potential for improving chick health, however future research should examine the in ovo
injection of different probiotic combinations with dietary probiotic supplementation
under pathogenic bacteria challenge.
Introduction
The use of commercial in ovo technology in the poultry industry has proven to be
an effective method for developing chick immunity before hatch (Sharma et al., 1984;
Peterson, 1984; Johnston et al., 1995). Through injecting an antigen into the amniotic
fluid of the egg on d 18 of incubation, the embryo is exposed to the vaccine prior to hatch
through skin contact, eye contact, and consumption of the vaccine (Negash et al., 2004).
During the early stages of in ovo technology development, it was noted that the injected
antigen can be isolated from the chick’s lymphatic tissues at hatch (Sharma and
Burmester, 1982). Therefore, this method of vaccination exhibited early development of
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immunological memory that provides the chick, whose immune system is still developing
upon hatch, with a physiological advantage in the grow-out facility (Gildersleeve et al.,
1993; Johnston et al., 1995; Schijns et al., 2014).
Although the poultry industry currently utilizes in ovo technology on d 18 of
incubation to vaccinate for Marek’s disease using the turkey herpes virus (HVT) vaccine,
interest has developed towards other beneficial products that could be introduced prior to
hatch (Reddy et al., 1996, Dalloul et al., 2005; Toro et al., 2007; Yair et al., 2015; Sokale
et al., 2017). This includes the injection of vitamins, sugars, phytogenics, prebiotics,
probiotics, or synbiotics to potentially enhance chick health and viability post-hatch
(Libby et al., 1955; Dalloul et al., 2005; Haghighi et al., 2006; Maiorano et al., 2012; Lee
et al., 2014; Oliveira et al., 2014; Sławińska et al., 2014; Płoweic et al., 2015;
Pruszynska-Oszmalek et al., 2015; Yair et al., 2015; Triplett et al., 2017; Pender et al.,
2017; Teague et al., 2017; Araújo et al., 2018; Castañeda et al., 2019). In some of these
studies, presenting the embryo with beneficial supplements, such as probiotics and
synbiotics, stimulated immunological components within the chick by the time of hatch
(Sławińska et al., 2014; Płoweic et al., 2015; Pender et al., 2017).
Due to increasing prevalence in antibiotic resistant bacteria and the development
of regulatory legislation for the use of antibiotics in food animals, research emphasis has
been placed on discovering a viable antibiotic alternative. One of these alternatives is a
probiotic, which is a beneficial bacteria species commonly found in the gastrointestinal
tract of its host (Fuller, 1989). Previous research on the feed supplementation of
probiotics has exhibited the beneficial bacteria’s role in immunomodulation of the gut
and regulation of the gastrointestinal microbiome (Kabir et al., 2004; Delcenserie et al.,
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2008; Neu, 2007; Li et al., 2009; Salah et al., 2012; Hassanpour et al., 2013; Plaza-Díaz
et al., 2018). Similarly, the supplementation of probiotics in poultry feed has yielded
improvements to live performance parameters by increasing body weight gain,
decreasing FCR, and decreasing pathogen presence in the gut (Rahimi and Khaksefidi,
2006; Mountzouris et al., 2007; Awad et al., 2009; Aliakbarpour et al., 2012; Tsirtsikos et
al., 2012; Jeong and Kim, 2014; Bai et al., 2017).
With promising results concerning dietary probiotic supplementation, research
has been conducted to assess the manual in ovo injection of probiotic bacteria and its
impacts on the embryo’s ability to hatch. Many of these studies have utilized cocktails of
probiotics or synbiotics that either produce organic acids or produce bacteriocidal
bacteriocins (Sławińska et al., 2014; Płoweic et al., 2015; Pruszynska-Oszmalek et al.,
2015; Pender et al., 2017; Teague et al., 2017). Within these studies, none have analyzed
the potential to in ovo inject probiotics with differing modes of action (Haghighi et al.,
2006; Oliveira et al., 2014; Sławińska et al., 2014; Płoweic et al., 2015; PruszynskaOszmalek et al., 2015; Pender et al., 2017; Teague et al., 2017; Triplett et al., 2017). By
providing a late-stage chicken embryo with various probiotics that have different modes
of action, one may be able to stimulate early development in the gastrointestinal
microflora and enhance the chick’s gut epithelial barrier upon hatch (Dibner et al., 1998;
Roto et al., 2016). Along with potentially improving the health of the gastrointestinal
tract, in ovo probiotic injections may influence the regulation of pro-inflammatory and
anti-inflammatory cytokines (Sławińska et al., 2014; Płoweic et al., 2015) as well as
immunological gene expression within the gut (Pender et al., 2017).
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A viable contender for in ovo probiotic injection is Lactobacillus animalis
(Haghighi et al., 2006; Oliveira et al., 2014; Sławińska et al., 2014; Płoweic et al., 2015;
Pruszynska-Oszmalek et al., 2015; Pender et al., 2017; Teague et al., 2017; Triplett et al.,
2017). Lactobacillus spp. are non-spore forming, gram positive cocci (Tannock, 1992).
The bacteria secrete lactic acid into its immediate environment, which decreases the
environmental pH and makes it difficult for other bacteria species that are sensitive to pH
to remain in the same environment (Hutkins and Nannen, 1993; Balcázar, 2007).
Concurrently, studies have observed that Lactobacillus spp. are able to maintain high
populations within the gastrointestinal tract due to their high adhesion to the epithelial
lining (Tannock, 1992; Barrangou et al., 2012).
Another probiotic who has the potential for in ovo probiotic vaccination is
Bacillus licheniformis (Oliveira et al., 2014). Bacillus spp. are gram positive, sporeforming rods (Cutting, 2011). Concurrently, the Bacillus spp. secrete both bacteriocidal
and bacteriostatic bacteriocins that influence the bacteria populations present in the
surrounding environment (Cutting, 2011). Bacillus spp. have become a desirable
probiotic for in-feed probiotic supplementation in the poultry industry, primarily due to
its heat and pH resistance while in a sporulated state (Leser et al., 2007; Cutting, 2011).
Both Lactobacillus spp. and Bacillus spp. have been identified in different portions of the
gastrointestinal tract of poultry (Lu et al., 2003).
As previously stated, the potential for in ovo probiotic injection as a viable
antibiotic alternative has been observed (Haghighi et al., 2006; Maiorano et al., 2012;
Oliveira et al., 2014; Pender et al., 2017; Teague et al., 2017; Triplett et al., 2017).
However, many of these studies conduct in ovo injection procedures by hand, inject
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greater volumes of diluent than the 50 µl standard used by commercial in ovo technology,
and only inject a single species of probiotic or a cocktail of probiotics with similar modes
of action (i.e. lactic acid production). Many of these studies have not conducted a
complete grow-out after hatch and have not challenged the chicks that were in ovo
supplemented with pathogens common in the grow-out facility. Therefore, the present
study evaluates the influence of the in ovo injection of L. animalis, B. licheniformis, and
their combination using commercial Inovoject® technology on hatch performance, live
performance over a 49 d grow-out, and immunological parameters (circulating white
blood cell counts, cytokine quantification, bursa follicle size, and gastrointestinal lesion
scores) before and after a coccidiosis challenge.
Materials and Methods
In vitro Analysis of Probiotic Cultures
Growth at 12 and 24 hours of incubation at 37˚C in selective broth was measured
for each probiotic bacteria individually. Desirable incubation time where growth reached
106 cfu/mL was established for L. animalis (ATCC 35046) grown in De Man, Rogosa
and Sharpe Broth (MRS; Millipore Sigma, St. Louis, MO) and for B. licheniformis
(ATCC 11945) in Tryptic Soy Broth (TSB; Millipore Sigma, St. Louis, MO).
Egg Incubation
A total of 2,880 fertile Ross 708 broiler hatching eggs from a 39 week old broilerbreeder flock were purchased from a commercial hatchery. Eggs were assessed for
cracked or misshaped shells and individually labelled by egg number, flat, and treatment
where 21 flats (630 eggs) were assigned to each treatment. To set eggs for incubation,
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flats were arranged evenly throughout 3 NatureForm® setter units (NatureForm Hatchery
Technologies, Jacksonville, FL). Eggs were candled on d 10 to remove infertile, cracked
and contaminated eggs. 4 treatments were applied on d 18 using commercial Inovoject®
equipment (Zoetis, Parsippany, NJ) and eggs were transferred to hatching baskets and set
in Georgia Quail Farm® hatcher units (Georgia Quail Farm, Savannah, GA; 3 GQF
hatchers/treatment).
Injection Procedure
Probiotic bacteria cultures were prepared the day prior to injection. On d 18 of
incubation, commercial Inovoject® technology (Zoetis Inc., Parsippany-Troy Hills, NJ)
was utilized to apply treatments to the developing eggs. Embryo staging was conducted
during the injection process where 1 egg was collected from each flat for analysis.
Selected eggs (6 eggs/treatment, 24 total eggs) were injected with 50 µl R-250
Coomassie blue dye (Thermo Fisher Scientific, Waltham, MA) and immediately
euthanized via CO2 asphyxiation. For the remaining eggs, the treatments were applied.
Every treatment was combined in 800 mL of sterile diluent (Merial Select Inc.,
Gainesville, GA) prior to injection with Marek’s Disease (HVT) vaccine (Merck & Co.
Inc., Madison, NJ). The composition of sterile diluent is sterilized reverse osmosis water.
One flat was injected at a time, with all eggs in the flat injected at once. The injected
treatments were as follows: 1.) HVT vaccine (control), 2.) L. animalis (~106 cfu/50μL) +
HVT vaccine, 3.) B. licheniformis (~106 cfu/50μL) + HVT vaccine, 4.) L. animalis (~106
cfu/50μL) + B. licheniformis (106 cfu/50μL) + HVT vaccine. Immediately after injection,
eggs were placed in the hatcher unit. A sanitation cycle recommended by Zoetis was
completed between each treatment, and microbial samples were collected after each
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sanitation cycle using tryptic soy agar plates (TSA; Millipore Sigma, St. Louis, MO) to
ensure that no contamination occurred from the in ovo equipment. Inoculated TSA plates
were incubated aerobically at 37˚C. Eggs were set in a manner to prevent contamination
between treatments, where each treatment occupied three GQF hatchers (12 GQFs total).
Hatch Procedure
On day of hatch, hatched chicks were counted, weighed, and sexed by wing
feather sexing (“Ross Broiler Management Manual”, 2009). Hatch residue analysis was
conducted where unhatched eggs were counted and classified as early dead, mid dead,
late dead, infertile, contaminated, cracked, or culled. Male chicks from the hatch were
placed in pens of 18 chicks/pen according to treatment within a grow-out facility.
Research pens in the house were arranged in a way to prevent cross contamination where
no pen had contact with the other pens around it.
Grow-out Procedure
Male chicks from the hatch were placed in pens of 18 chicks/pen according to
treatment within a grow-out facility at a stocking density of 0.20 m2/chick. A 49 d growout was carried out after hatch. An industry standard corn/soy bean meal basal diet was
formulated according to Ross 708 guidelines without antibiotics, anticoccidials, or
antibiotic alternatives. Food and water were supplied ad libitum. Chick mortality, body
weight gain, and feed consumption were observed. A coccidiosis challenge was
conducted on d 14 of the grow-out. A 20X dosage of Coccivac®-B52 (Intervet Inc.,
Omaha, NE) consisting of live E. acervulina, E. maxima, E. maxima MFP, E. mivati, and
E. tenella live oocysts were introduced to all birds via 1 ml oral gavage (768 chicks, 16
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chicks/pen on d 14). All animals in this trial were treated in compliance with the Guide
for the Care and Uses of Agriculture Animals in Research and Teaching (Federation of
Animal Science Societies, 2010) and the Mississippi State University Institutional
Animal Care and Use Committee (IACUC Animal Welfare Assurance #A3160-01).
Immuno-physiological Response Analysis
Immunological tissues were collected during the grow-out to measure immunophysiological responses in the broiler chicks. Whole blood was collected on d 0, 21, and
28, and whole bursas were collected on d 0, 7, 14, 21, and 28. Spleen and bursa weights
were also collected on d 0, 7, 14, 21, 28, and 49.
Bursa Weight relative to Body Weight
Bursa weights were collected during each sampling day (d 0, 14, 21, 28 and 49).
Gross tissue weight and bursa weight relative to body weight were calculated. 12
bursas/treatment/day were weighed and fixed in 10% neutral buffered formalin for
further analysis (Fisher Scientific, Hampton, NH).
Bursa Follicle Area
A 0.3 cm section of bursa was segmented along the sagittal plane. The section
was fixed in a Unisette™ Biopsy Cassette (Ted Pella, Inc., Redding, CA), sectioned
using a microtome, fixed onto microscope slides, and stained with hematoxylin and eosin
by the Mississippi State University College of Veterinary Medicine Diagnostic Lab
(Mississippi State, MS). Bursa follicles from each sample were measured at 4X
magnification using the Infinity Analyze system (Microscope World, Carlsbad, CA) to
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measure follicular area (μm2). Three folds were measured for each sample slide, and 3
follicles were measured on each fold and (9 measurements/bursa sample).
Total White Blood Cell Counts
Blood smears were conducted on d 0, 21 and 28. Slides were stained using Wright
Stain (Sigma-Aldrich, Inc., St. Louis, MO). Under 40X magnification, heterophil,
lymphocyte, eosinophil and total white blood cell counts were taken from 10 entire
frames at 40X/sample slide.
Cytokine Quantification
Cytokine quantification using collected blood serum was conducted using
Quantibody Chicken Cytokine Array Q1 (RayBiotech Life, Norcross, GA). Microarray
slides images were captured using a ScanArray Express Microarray scanner at 100 Power
and 750 PMT (PerkinElmer, Inc., Waltham, MA). Intensity of the spot fluorescence on
microarray slides was measured using the Spotxel program (Sicasys Software GmbH,
Heidelberg, Germany). Normalization and analysis of fluorescence was completed using
the Cytokine QAG-CYT-1 Q-Analyzer v8.10.4 (RayBiotech Life, Norcross, GA).
Gastrointestinal Tissue Sampling
One bird from each pen (12 pens/treatment) was randomly selected for sampling.
Gastrointestinal and lymphatic tissue samples were collected on d 0, 7, 14 (prior to
coccidiosis challenge), 21, 28 and 49 of the grow-out. Tissue weights with contents for
the duodenum, jejunum, ileum, ceca, bursa and spleen were recorded. Lesion scoring was
conducted in a one cm2 segment of the duodenum, jejunum, ileum and ceca on d 21 and
28, where each observed segment was given a score of 0 (indicating no lesion presence),
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1, 2, 3, or 4 (indicating severe, hemorrhagic lesions) according to guidelines established
by Edgar (2007).
Statistical Analysis
SAS v. 9.4 (SAS Institute, Cary, NC) was used to conduct statistical analyses.
Incubation data was analyzed using a completely randomized design. The experimental
unit was GQF hatcher unit (3 GQFs/treatment). Live performance was analyzed using a
randomized complete block design. The experimental unit was pen (12 pens/treatment).
Lesions scores were analyzed using a randomized complete block design with a split plot
over time. Immunological data was analyzed using a completely randomized design with
a split plot over time (6 pens/treatment). Means were separated using Fisher’s Protected
LSD and differences were considered significant when P ≤ 0.05 (Steel and Torrie, 1980).
Results
Verification of the Injection Procedure
A standard sanitation cycle was run within the Inovoject® machine between each
treatment application, and samples from the injection needles were collected after each of
these cycles. In all of the collected microbiological samples, no bacterial growth was
observed on the TSA plates. This indicates a successful sanitation between each
treatment where no residual probiotic bacteria was left within the machine. After the
injection procedure, embryo staging was conducted to ensure that the in ovo vaccination
occurred in the correct location within the egg during the correct stage of development. It
was determined that embryos were at d 18 of embryonic development and exhibited a trilobed yolk sac with intestines enclosed within the body cavity. The coomassie blue dye
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that was injected was present on the feathers of the embryos, indicating that the in ovo
vaccination hit the amniotic sac. The concentration of the injected probiotic treatments
was also verified on TSA and MRS agar. Probiotic concentrations for each treatment
were as follows: no bacterial growth in the HVT control treatment on TSA or MRS agar,
1.5 X 107 cfu/50 μL of L. animalis and 0 cfu/50 μL of B. licheniformis on MRS agar in
the L. animalis treatment, 0 cfu/50μL of L. animalis and 3.3 X 106 cfu/50μL of B.
licheniformis on TSA in the B. licheniformis treatment, and 2.5 X 107 cfu/50 μL of L.
animalis on MRS agar and 3.0 X 106 cfu/50 μL of B. licheniformis on TSA agar for the
combination treatment.
Hatch Parameters
No differences were observed between treatments in percent hatch of transfer,
which refers to all eggs transferred to hatcher units on d 18 of incubation after the
application of treatments (P=0.61; Table 4.1). No differences were also observed among
treatments for average chick weight (P=0.39; Table 4.1). Similarly, hatch residue
analysis observed no differences between treatments in percent pipped, percent cracked,
percent contaminated or percent cull eggs (P>0.05; Table 4.1). However, the B.
licheniformis treatment yielded significantly lower percent late dead eggs when compared
to the HVT control treatment, but percent late dead eggs of the L. animalis and the
combination treatments were not significantly different from the control or B.
licheniformis treatments (P=0.04; Table 4.1).
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Immuno-physiological Parameters
Total White Blood Cell Counts
Treatment main effects were observed in total white blood cell (WBC) counts and
percent heterophils between treatments (P=0.02 and 0.01, respectively; Table 4.2). For
total WBC counts, birds of the L. animalis treatment yielded elevated counts when
compared to the combination treatment, but both the L. animalis and the combination
treatments were not different from the HVT control or B. licheniformis treatments.
Alternatively, birds of the B. licheniformis and the combination treatments observed
greater percent heterophils when compared to the HVT control (P=0.01).
A treatment by day interaction was observed for percent lymphocytes (Figure
4.1; P=0.005). On d 0, birds of the B. licheniformis and L. animalis treatments yielded
elevated levels of percent lymphocytes when compared to the birds of the HVT control
but both treatments were not different from the birds of the combination treatment. On d
21, birds belonging to the B. licheniformis and combination treatments yielded greater
percent lymphocytes when compared to birds of the HVT control and L. animalis
treatments. On d 28, birds belonging to the combination treatment observed significantly
greater percent lymphocytes when compared to birds of the B. licheniformis treatment but
were not different from L. animalis or the HVT control treatments.
Bursa Weight and Follicular Area
No treatment by day interactions were observed for bursa weight relative to body
weight or gross bursa weight; however, trends may exist in these data (P=0.062 and
P=0.7, respectively; Figure 4.2 and Figure 4.3, respectively). Upon hatch, it appears that
L. animalis yielded a larger relative bursa weight than the other treatments, and this was
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maintained until d 7. On d 14 and d 28, birds of the B. licheniformis and the combination
treatments appear to yield heavier relative bursa weights than the other treatments
(Figure 4.2). Unlike the relative bursa weights, no prominent trends appear in the
treatments until d 49 in gross bursa weight. On d 49, birds of the L. animalis treatment
appears to yield a heavier bursa than the other treatments (Figure 4.3). For average bursa
follicle area, birds of the L. animalis and control treatments yielded a numerically larger
follicle area on d 28 (P=0.051; Figure 4).
Spleen Weight
Spleen weight relative to body weight and gross spleen weight were observed
(P=0.057 and P=0.2, respectively; Figure 4.5 and Figure 4.6, respectively). Relative
spleen weight for birds of the combination treatment had heavier relative spleen weights
on d 0. However, the birds from the HVT control treatment appear to yield heavier
relative spleen weights than the other treatments on d 7 and d 14. By d 28, the birds of the
B. licheniformis treatment appeared to yield heavier relative spleen weights than the other
treatments. On d 49, birds belonging to the L. animalis and B. licheniformis treatments
appear to yield relative spleen weights heavier than the HVT control and combination
treatments (Figure 4.5). Although less prominent, gross spleen weight did indicate that
birds of the L. animalis and B. licheniformis yield heavier gross spleen weights when
compared to the other treatments on d 49 (Figure 4.6).
Cytokine Quantification
Treatment by day interactions were observed in Interleukin (IL)-6, IL-10, IL12p40, IL-16 and IL-21 (P<0.05; Figure 4.7, 4.8, 4.9, 4.10 and 4.11, respectively). On d
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0, B. licheniformis yielded elevated IL-6, IL-12p40 and IL-16 cytokines when compared
to all other treatments. Also on d 0, the combination treatment observed elevated IL-16
levels compared to the control treatment but was not different from the L. animalis
treatment. No differences were observed between treatments among the cytokines tested
on d 21. However, on d 28, B. licheniformis yielded elevated IL-10 levels and the
combination yielded elevated IL-21 levels when compared to all other treatments.
Live Performance Parameters
No differences were observed in mortality or live weight gain between treatments
during all phases of the grow-out (d 0-14, d 14-28, d 28-49, d 0-28 or d 0-49). However,
there was a difference in FCR during the d 14-28 phase only where the L. animalis
treatment yielded an FCR greater than the HVT control and B. licheniformis treatments
(P=0.03; Table 4.3). However, no other significant differences were observed in FCR
during the d 0-14, d 28-49, d 0-28 or d 0-49 phases.
Gastrointestinal Tissue Weights
Treatment by day interactions were observed in the ileum (with contents) for
tissue weight relative to body weight and for gross ileum weight (P=0.03 and P=0.03,
respectively; Figure 4.12 and Figure 4.13, respectively). On d 0, no differences among
treatments were observed in the relative tissue weight of the ileum. On d 7, the relative
tissue weight of the ileum was significantly higher in the B. licheniformis treatment when
compared to all other treatments. Similarly, on d 14, the relative tissue weight of the
ileum was higher in the B. licheniformis and combination treatments compared to the
control and L. animalis treatments. No other treatment by day interactions were observed
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in the relative tissue weight of the ileum on d 21, d 28 or d 49 (Figure 4.12). However,
on d 28, the gross tissue weight of the ileum for the combination treatment was found to
be greater than the gross ileum weights of all other treatments. By d 49, the combination
treatment yielded a gross tissue weight for the ileum that was significantly smaller than
those of the L. animalis treatment but not different from the tissue weights of the HVT
control or the B. licheniformis treatments (Figure 4.13).
No treatment by day interactions were observed for gross ceca weight or ceca
weight relative to body weight (with contents), trends may be evident (P=0.052 and
P=0.56, respectively; Figure 4.14 and Figure 4.15, respectively). On d 0, birds of the B.
licheniformis and the combination treatments exhibit heavier relative ceca weights when
compared to the HVT control and L. animalis tissue weights. However, this appears to be
lost by d 14 (Figure 4.14). No differences were evident until d 21 for gross ceca weights
where the combination yields a smaller gross tissue weight when compared to all other
treatments. By d 49, the gross ceca weight was larger in birds belonging to the B.
licheniformis and combination treatments (Figure 4.15).
Gastrointestinal Lesion Scores
No differences were observed in the incidence of red or white lesion scores (with
a score of 0, 1, 2, 3, or 4) in the duodenum, jejunum, ileum, or ceca on d 21 or d 28
among all treatments (P>0.05; Table 4.4 and 4.5, respectively). However, an effective
coccidiosis challenge is apparent due to all treatments exhibiting an incidence of a lesion
score of at least 1 in the duodenum, jejunum, and ileum.
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Discussion
Hatch Parameters
From the results of this study, it was determined that neither L. animalis, B.
licheniformis, nor their combination decreased hatch performance when in ovo injected
on d 18 of incubation. Although there were no differences in hatch between the
treatments, a significant difference in percent late dead eggs was observed where the
HVT control treatment yielded greater numbers of late dead eggs when compared to the
B. licheniformis treatment. Concurrently, no significant differences were observed in
percent contaminated eggs among treatments. This is a favorable attribute for the in ovo
injection of probiotics, as it exhibits that live, beneficial bacteria cultures can be injected
into a fertile broiler hatching egg on d 18 of incubation without causing contamination in
the egg prior to hatch. These results concur with previous studies who have conducted in
ovo probiotic injections (Pender et al., 2017; Teague et al., 2017; Triplett et al., 2017;
Castañeda et al., 2019). Previous research has observed that organic acid-producing
bacteria such as Lactobacillus spp. and Bifidobacterium spp. are competent probiotic
species that can be injected in ovo without harming the developing embryo (Yamawaki et
al., 2013; Oliveira et al., 2014; Pender et al., 2017; Triplett et al., 2018).
However, several studies have found that the species of probiotic injected has a
major influence on hatch performance (Oliveira et al., 2014; Triplett et al., 2018). Triplett
et al. found that the in ovo injection of Bacillus subtilis (ATCC 6051) significantly
decreased percent hatched chicks when compared to the positive and negative control
groups where the hatchability dropped below 10% (2018). The other probiotic treatments,
such as Lactobacillus acidophilus and Bifidobacterium animalis, did not observe any
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severe negative influences from the probiotic injection (Triplett et al., 2018). This may be
due to the toxic bacteriocins, such as 2,3-butanediol, secreted by certain subspecies of B.
subtilis, which have been found to induce abortions in mice (Nicholson et al., 2008;
Gendron and Baines, 1987; Lai et al., 2012). Oliveira et al. (2014) determined that the
injection of probiotic bacteria cocktails containing various Bacillus spp. or Lactobacillus
spp. yielded highly variable hatch performances. Some of these treatments yielded
hatchability as low as 10%, while other treatments were able to maintain 80-90%
hatchability (Oliveira et al., 2014). The results from Triplett et al. (2018) and Oliveira et
al. (2014) may indicate that probiotics, even within a single species, can impact its host
differently and thereby influence the embryo’s ability to hatch (Lin et al., 2009;
Slawińska et al., 2014; Ploweic et al., 2015; Pender et al., 2017; Teague et al., 2017).
However, it is important to emphasize that these negative impacts were not observed in
the present trial with the injection of Bacillus licheniformis or Lactobacillus animalis.
Cytokines
Recent studies have noted that the gut microbiome is closely linked to immune
response and disease development within the host (Cash et al., 2006; Bouskra et al.,
2008; Wen et al., 2008; Round and Mazmanian, 2009; Franchi et al., 2012). In mice, it
was observed that high fat diets induce Type 1 diabetes and obesity through observed
manipulations in the gut microbiome (Cani et al., 2007; Wen et al., 2008; de La Serre et
al., 2010). Autoimmune and inflammatory gut diseases in humans appear to be capable of
altering the gastrointestinal microbiome, where lactic acid producing bacteria presence
was decreased in people suffering from those diseases (de La Serre et al., 2010).
Similarly, commensal bacteria of the gut appear to be capable of regulating cytokine
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proliferation and activity (Franchi et al., 2012). Concurrently, the regulation of cytokines
by heterophils, macrophages, NK cells, and lymphocytes (such as T cells and B cells) are
usually associated with gastrointestinal inflammation caused by pathogenic agents and
genetic factors (Kaiser et al., 2006; Franchi et al., 2012). The influences of disease on the
gut microbiome has been noted in many species in many animal models (Bouskra et al.,
2008; Knapp et al., 2010; Franchi et al., 2012; Šlapeta et al., 2015). In an attempt to
manage the inflammatory effects of these physiological abnormalities, research has
observed that the supplementation of probiotics in a diet may be capable of reducing
gastrointestinal inflammation (Delcenserie et al., 2008; Lin et al., 2009; Wagner et al.,
2009; Mountzouris et al., 2010; Li et al., 2015)
Through the in ovo injection of probiotics, it is predicted that the introduced
probiotics will develop the chick’s gastrointestinal microflora in a beneficial manner and
provide the newly hatched chick with an advantage against pathogens in the grow-out
facility (Pender et al., 2016; Gao et al., 2017). Castañeda et al. (2019) evaluated the
colonization of bioluminescent-labeled E. coli when injected into the amnion or air cell of
broiler hatching eggs on d 18 of incubation. When the labeled bacteria were injected into
either the amnion or the air cell, at least 3 logs of the labeled, in ovo injected E. coli in the
crop, duodenum, jejunum, ileum, and ceca upon hatch (Castañeda et al., 2019). This
study exemplifies the potential for stimulating early gastrointestinal microflora and
immune system development through the in ovo injection of probiotics.
In the present study, the in ovo injection of L. animalis, B. licheniformis, or their
combination elicited physiological changes among treatments under a coccidiosis
challenge. B. licheniformis exhibited elevated quantities of pro-inflammatory cytokines
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(IL-6, IL-12p40, and IL-16) on d 0 when compared to all other treatments on all other
days. The combination treatment also yielded elevated IL-16 levels when compared to
the control on d 0. IL-16 belongs to a non-multigene family of cytokine that exhibits
chemokine-like capabilities that attract eosinophils and monocytes to a location to react
to an antigen (“Interleukin-16”, 2019). IL-12p40 is a Th 1 cytokine that exhibits pro- and
anti-inflammatory responses for controlling intracellular pathogens and regulating
antiviral activity (“Interleukin-12p40”, 2019). IL-6 is a non-multigene cytokine that is
present early in an infection and is essential for B cell and antibody differentiation
(“Interleukin-6”, 2019).
These results indicate that the in ovo injection of probiotics, particularly B.
licheniformis and the combination of B. licheniformis and L. animalis in the present
study, are capable of stimulating the immature immune system of the chick upon hatch
without negatively influencing chick quality. These cytokines are known for their aid in
immune cell proliferation and antigen recognition, which may be indicative of a negative
response to the supplemented probiotics. However, no negative influences were observed
in hatched chick weight, body weight gain, or FCR during the first 7 days of grow out as
well as over the course of the entire grow out (d 0-49).
It is also pertinent to discuss that two interleukins observed significant
upregulation by d 28. B. licheniformis increased IL-10 presence when compared to all
other treatments and the combination increased IL-21 when compared to all other
treatments on d 28. IL-10 and IL-21 are both proliferative, T cell-derived cytokines
which participate in the development of T and NK cells (“Interleukin-10”, 2019;
“Interleukin-21”, 2019). Although IL-10 is noted for its anti-inflammatory mechanisms in
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diseases such as colitis (Kühn et al., 1993), the prevalent role of IL-21 is the proliferation
and differentiation of T helper cells and their subsequent ability to secrete cytokines (Fina
et al., 2008). This function, in turn, has been associated with upregulations in IL-21
during gastrointestinal inflammation (Fina et al., 2008).
These observations coincide with the results observed in the present study (Fina et
al., 2008). The upregulation of IL-21 in the combination treatment on d 28 corresponds
with an increase in percent lymphocytes in the combination when compared to the B.
licheniformis treatment on d 28. Concurrently, the combination treatment had a higher
incidence of a red lesion score 1 in the duodenum and a higher incidence of a white
lesion score of 2 in the jejunum when compared to B. licheniformis and the HVT control
on d 28. The combination also yielded a higher incidence of a red lesion score of 1 in the
ileum when compared to B. licheniformis and L. animalis on d 28. From these results, it
is possible that the in ovo injection of B. licheniformis may provide the chick with an
advantage against a challenge that may occur during the grow-out (such as coccidiosis).
However, these potential benefits may not be observed with the inclusion of B.
licheniformis in the combination treatment when injected in ovo.
Previous research has found that a bird’s immune system reacts in a dynamic,
enduring manner when under a coccidiosis challenge (Lillehoj, 1987; Laurent et al.,
2001; Rothwell et al., 2004; Hong et al., 2006; Collier et al., 2007). It is a common
understanding that coccidiosis has detrimental effects on a bird’s gut health and live
performance (Shivaramaiah et al., 2014). In poultry, the disease is caused by various
Eimeria spp., where each respective species infects a different region of the bird’s
gastrointestinal tract. Infection occurs when a bird consumes oocysts that sporulate within
116

the bird’s gut, adhere to and develop within the epithelial lining of the gut, and then
rupture from the epithelium to continue growth (Edgar, 2007). These ruptures in the
epithelium lead to Clostridium perfringens infections, in turn leading to poor bird health
and performance through necrotic enteritis (Collier et al., 2007; Edgar, 2007). It was also
determined that a coccidiosis challenge stimulates the production of cytokines, such as
IL-6 and IL-10, and immunoglobulins in both healthy and immunosuppressed birds
(Lillehoj, 1987; Lillehoj and Trout, 1996; Laurent et al., 2001; Hong et al., 2006). These
responses provide the chick with long-lasting immunity towards specific Eimeria spp.
after the initial infection (Lillehoj et al., 2004).
In the present study, all birds were challenged on d 14 of grow-out with a 20X
dosage of Coccivac-B52®, which contains E. acervulina, E. maxima, E. maxima MFP, E.
mivati, and E. tenella. E. acervulina resides in the duodenum and jejunum, E. tenella
resides in the cecal pouches, and both E. mivati and E. maxima both reside in the entire
small intestines (Edgar, 2007). In the present study, all treatments observed birds with
lesions on d 21 where white lesions yielded a score of at least 1 in the duodenum and red
lesions yielded a score of at least 1 in the jejunum. However, no treatment by day
interactions were observed among treatments on d 21 or d 28 in any severity of score or
tissue measured.
Although no differences in lesion scores were observed among treatments, B.
licheniformis yielded elevated levels of pro-inflammatory cytokines on d 0 and elevated
levels of anti-inflammatory cytokine IL-10 on d 28, which may indicate that the in ovo
supplementation of B. licheniformis potentially provided the chicks with an advantage
over the challenge and the ability to more rapidly resolve it. The birds in the L. animalis
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treatment yielded an elevated FCR during the coccidiosis challenge (d 14-28) when
compared to B. licheniformis and the HVT control treatment. Concurrently, the HVT
control and L. animalis treatments exhibited numerically higher percent mortality during
the coccidiosis challenge (d 14-28) as well as during the first half of the grow-out (d 028). However, these treatments exhibited a numerically lower percent mortality than the
B. licheniformis or combination treatments when analyzing the overall grow-out (d 0-49).
Therefore, this data may indicate that the in ovo injection of L. animalis may not be
influential in reducing the effects of a coccidiosis. This is hypothesized due to the fact
that an increase in the severity of a coccidiosis infection may lead to decreases in body
weight and increases in FCR (Conway et al., 1990).
Edgar et al. (2007) states that the time between initial infection and symptom
development for coccidiosis occurs on d 4 to 7 post-infection, with the sporulation of the
oocysts lasting 2 days after latching to the gut epithelium. Hong et al. (2006) found that
IL-6 spiked in levels 4 days post- E. acervulina challenge, however those levels
decreased by 7 days post-challenge. Similarly, it was noted that IL-17, a proinflammatory cytokine that regulates immune memory cells (Th17), was elevated by 10
days post- E. tenella challenge (Hong et al., 2006; “Interleukin-17”, 2019). Interestingly,
IL-21 (upregulated on d 28 in the combination treatment in the present study) is known to
promote the activities of T cells who produce IL-17 (Korn et al., 2007). Although IL-17
was not analyzed in the present study, further studies with cytokine regulation may
observe pivotal interactions among different cytokines during an inflammatory response
caused by coccidiosis.
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The results from Hong et al. (2006) may explain why no difference in cytokine
quantities were observed on d 21 in the present study; the cytokines may not have
observed an upregulation until a few days later in the infection (such as d 22 or d 23 of
the present study’s grow-out). Concurrently, the birds in these in ovo applied treatments
may resolve the coccidiosis challenge at different times during the grow-out. This may
explain the upregulation of the anti-inflammatory cytokine IL-10 in only the B.
licheniformis treatment on d 28. However, the results of the present study differ from
Laurent et al. (2001) where pro-inflammatory IL-1 and IFN-γ cytokines observed
upregulation by d 7 after an E. acervulina and E. maxima challenge.
White Blood Cell Counts
Interestingly, the hematological parameters of the in ovo injected chicks reacted
differently to a coccidiosis challenge when compared to the chicks of the control
treatment. Although L. animalis and B. licheniformis yielded elevated percent
lymphocytes when compared to the HVT control on d 0, B. licheniformis and the
combination exhibited elevated percent lymphocytes when compared to the L. animalis
and the control by d 21 (7 days after the coccidiosis challenge). By d 28, the percent
lymphocytes from the B. licheniformis treatment was significantly less than those of the
combination treatment but not different from the HVT control and L. animalis treatments.
Moreover, these results indicate that the in ovo injection of different probiotics, L.
animalis and B. licheniformis, alter the chick’s immunological traits upon hatch.
The innate immune system is the first line of defense for an organism, which
consists of white blood cells (such as heterophils, lymphocytes, macrophages and
basophils) that facilitate initial recognition and neutralization of an antigen within the
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body (Glick, 1986; Erf, 2004). Therefore, it is commonly accepted that an elevation in the
heterophil:lymphocyte (H:L) ratio is indicative of increased stress within a bird (Zulkifli
et al., 2000). Unlike this study, previous research has found that the supplementation of
probiotics, such as Bacillus spp. and Lactobacillus spp., in feed has led to a decrease in
WBC counts and a decrease in H:L ratios (Rahimi and Khaksefidi, 2006; Wagner et al.,
2009; Li et al., 2015). Concurrently, Li et al. (2009) observed that Bacillus
amyloliquefaciens decreased percent lymphocytes in broilers when under a
lipopolysaccharide challenge. Rahimi and Khaksefidi (2016) observed that an inclusion
of a Bacillus subtilis-based probiotic in the diet without any challenged condition lead to
an increase in total white blood cell counts and a decrease in the H:L ratio by d 42 of a
grow-out. Alternatively, Munyaka et al. (2012) determined that the inclusion of a yeastbased product yielded elevated H:L ratios in birds at 42 d of grow-out. Although this
elevation in a variable used for stress indication was present, Munyaka et al. (2012) noted
that birds did not undergo a challenge and did not exhibit and increased FCR.
In the present study, no main effects or treatment by day interactions were
observed among treatments for the H:L ratio. Therefore, the results of this study and
previous studies reveal that the introduction of probiotics may modulate the
gastrointestinal tract in a manner that provides an enhanced protective barrier against
pathogens due to an increase in circulating white blood cells (Al-Gwaiz and Babay, 2007;
Mardi et al., 2009). The birds that received an in ovo supplementation of a probiotic may
have developed a physiological advantage against a challenge in the grow-out facility,
such as coccidiosis, which resulted in modulations to circulating white blood cells.
Concurrently, these studies may indicate that the level of stimulation in the immune
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system is dependent on both the challenge conditions as well as the probiotic being used
to alleviate these challenges (Rahimi and Khaksefidi, 2006; Al-Gwaiz and Babay, 2007;
Mardi et al., 2009; Wagner et al., 2009; Munyaka et al., 2012; Li et al., 2015).
As previously stated, pro-inflammatory cytokines are commonly associated with
T and B cell proliferation when the host is under challenged conditions. The higher levels
of pro-inflammatory interleukins on d 0 in the B. licheniformis may have led to an
increase in circulating lymphocytes, as it is known that pro-inflammatory cytokines are
produced by white blood cells to attract B and T cells (Wigley and Kaiser, 2003).
However, all probiotic treatments observed elevated percent lymphocytes on d 0 when
compared to the control. Although no differences were observed among treatments in any
of the pro-inflammatory or anti-inflammatory cytokines on d 21 in the present study, it is
necessary to address that the anti-inflammatory interleukin (IL-10) was upregulated by d
28. B. licheniformis yielded a significant increase in IL-10 when compared to all other
treatments on d 28, which may be an explanation for why B. licheniformis also exhibited
a decrease in percent lymphocytes when compared to the combination on d 28. As these
perceived inflammatory responses in the gut tissue were resolved, the birds may have
exhibited a decrease in lymphocytes collecting around the infected tissue, which in turn
led to a resolution in the inflammation caused by the coccidiosis challenge (Glick, 1986;
Erf, 2004).
Lymphatic Tissue Weights and Bursa Follicle Area
Along with differences among percent lymphocytes, trends appeared to exist in
bursa tissue weights and bursa follicle area. B. licheniformis and the combination
treatments appear to observe a trend where the bursa follicle area decreases when
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compared to the HVT control and L. animalis treatments on d 28. Similarly, bursa weight
relative to body weight exhibit a trend where B. licheniformis treatments yields bursas
that are numerically heavier than the HVT control and L. animalis treatments on d 14 and
d 28. The bursa of Fabricius is a lymphatic organ located inferior to the cloaca and large
intestines (Glick, 1986). It functions as a primary region for B cell synthesis within the
inner follicles of the organ (Glick, 1986). Therefore the area of a bursa follicle is a
measurement for B cell production potential where an increase in bursa follicle are
indicates an increased potential for the bird to produce more B cells (Glick, 1986; Muniz
et al., 2006).
However, it is important to note the bursa is not the only source of B cells within
the bird’s body (Glick, 1956; Lillehoj and Trout, 1996). However, it has been discovered
that bursa follicular area is increased as the severity of a stressor increased, such as bird
stocking density (Muniz et al., 2006). In the present study, d 28 observed a numerical
decrease in bursa follicle area in B. licheniformis and the combination when compared to
L. animalis and the HVT control on d 28. This coincides with an increase in antiinflammatory cytokines, where B. licheniformis observed a greater quantity of IL-10 and
the combination yielded a greater quantity of IL-21. However, this is only a trend and
further studies are necessary to fully understand this relationship.
It is established that an increase in bursa follicle area is suggestive of a bird’s
stress level (Muniz et al., 2006), which may indicate that birds injected with L. animalis
and the HVT control were exhibiting a more extreme response to a stressful condition
(such as the coccidiosis challenge). Although this study only observed a trend in bursa
follicle area and bursa weight, further studies are crucial to understand the role that the in
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ovo injection of a probiotic has on the chick’s ability to manage stressful conditions, such
as a coccidiosis challenge, during grow-out. In the present study, it is important to note
that the birds injected with L. animalis yielded a higher FCR, a decrease in percent
lymphocytes on d 21, and a numerically higher bursa follicle area on d 28. Although a
decrease in percent lymphocytes may lead to an elevated H:L ratio, this was not observed
in the present study. Concurrently, further studies on circulating immunoglobulins may
be necessary to validate an upregulated humoral immune system.
Similarly to bursa tissue weight, a trend appears to exist between the in ovo
injection of a probiotic and spleen weight relative to body weight. Although no
significant differences were observed for the interaction, the probiotic treatments appear
to yield relative spleen weights numerically smaller than the control treatment on d 7 and
d 14. Treatments such as B. licheniformis and L. animalis also appear to numerically
increase spleen weight from d 28 to d 49. This is pertinent to note, as the spleen is a
lymphatic organ that is a crucial reservoir for the proliferation and circulation of various
T cells (Glick, 1986; Erf, 2004). When probiotics are supplemented in feed, Kabir et al.
observed that birds who consumed lactic acid-producing bacteria species yielded
significantly heavier spleens than the conventionally fed group by d 35 of the grow-out
(2004). These results may indicate that probiotic supplementation, whether in feed or in
ovo, can play a role in the development and modulation of lymphatic tissues and T cell
development throughout the body.
Live Performance and Gastrointestinal Tissue Weight
The diverse impacts that the probiotics used in the present study had on the
chick’s immune system may be an explanation for the differences observed in
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gastrointestinal tissues and live performance. The only difference in live performance
was in d 14-28 FCR, where L. animalis yielded a greater FCR when compared to B.
licheniformis or the HVT control. Interestingly, it appears that this data conflicts with the
gastrointestinal tissue weight results. B. licheniformis and the combination observed
greater ileum weights relative to body weight on d 14 when compared to the control and
L. animalis. Also, B. licheniformis observed greater relative ileum weights on d 7 when
compared to all other treatments. Previous research indicates that an increase in the
weight of gastrointestinal tissue may lead to an increase in FCR, however it has been
commonly observed that probiotic supplementation is also capable of increasing
gastrointestinal tissue weight without negatively influencing FCR (Coates et al. 1995; Jin
et al., 2000; Awad et al., 2009). Interestingly, a trend was observed in ceca weight
relative to body weight, where B. licheniformis and the combination treatments yielded
heavier ceca tissues than the HVT control and L. animalis on d 0. The results of this trial
are intriguing as they indicate that the in ovo injection of a probiotic can influence the
development of the gastrointestinal tract upon hatch as well as weeks after a single
supplementation prior to hatch.
Although lesions were present in the duodenum, jejunum, and ileum of all
sampled birds in all treatments on d 21 and d 28, there was no significant difference in
the percentage of birds that yielded a lesion score of 0, 1, 2, 3, or 4. For this reason, the
presence of lesions are indicative of a successful coccidiosis challenge, yet the in ovo
injected probiotic treatments were not capable of decreasing the incidence of lesions
when compared to the HVT control treatment. It is interesting to note that birds in the L.
animalis treatment yielded a numerically higher incidences of a lesion score of 2 in both
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red and white lesions in the duodenum and jejunum on d 21 and d 28 when compared to
the other treatments. However, these differences were not significantly greater.
These results may indicate that the in ovo injection of a probiotic bacteria on d 18
of incubation may be more effective when coupled with the supplementation of the
probiotic in feed. The increase in FCR on d 14-28 may be due to the probiotic bacteria
being incapable of maintaining presence in the gastrointestinal tract after d 7 of grow-out.
Bacillus licheniformis exhibits low adhesion to the mucosa of the gastrointestinal tract
but does secrete bacteriocins with bacteriocidal and anti-adhesive properties (Faille et al.,
2002; Cladera-Olivera et al., 2003). Alternatively, Lactobacillus animalis has exhibited
high mucosal adhesion capabilities and lactic acid secretion, specifically in the crop of
poultry (Fuller, 1973; Hutkins and Nannen, 1993; Ehrmann et al., 2002).
Due to low adhesive capabilities of B. licheniformis, the potentially positive
influences that it could have on the gastrointestinal tract may not be maintained several
days after in ovo injection. However, chicks in ovo injected with L. animalis, which
should maintain its presence within the gut due to its known adhesive abilities, exhibited
greater FCR through d 14-28 in the present study. Due to the bacteriocidal and
antiadhesive bacteriocin production of B. licheniformis, it is possible that the combined
injections B. licheniformis and L. animalis may influence the capacity that L. animalis
has in adhering to the mucosa of the gut in the combination treatment.
Overall Impacts and Future Directions from the Study
The results of this study indicate that the in ovo injection of two probiotic species
with two differing modes of action at the same time may be a viable practice in the
commercial broiler industry. The injected probiotics did not hinder the chick’s ability to
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hatch, and the supplementation exhibited immunomodulatory effects and physiological
activities within the growing chick upon hatch. The results of the present study may
exhibit the preparative influence that B. licheniformis and the combination may have on
chicks when injected in ovo. The chicks in these treatments observed differences among
immune parameters (such as an increase in anti-inflammatory cytokines on d 28 and an
increase in percent lymphocytes on d 21), which indicate that they may have underwent a
more rapid response to the coccidiosis challenge. This response may have occurred prior
to d 21, due to no upregulation in pro-inflammatory cytokines being observed on d 21 in
all treatments. Although there were no improvements to live performance overall, B.
licheniformis may have exhibited lower stress levels according to the hematological
parameters collected. However, this relationship must be further explored in future
research.
Although no treatment by day interactions were observed for bursa weight in this
study, the data collected may indicate that L. animalis is less impactful on the immune
system of the chick when injected in ovo. However, it is pertinent to address that bursa
weight alone is not an indication of an elevated immune response (Glick, 1963). Even so,
it is impressive that the in ovo injection of probiotics with differing modes of action is
able to influence the physiological development of the immune system. Concurrently,
this influence appears to impact how a bird responds to a challenge, where different
immune response mechanisms appear to expend energy within the bird diversely.
Even though these beneficial attributes were observed, this early supplementation of a
probiotic may not provide the chick with comprehensive protection against a challenge
later in life. Therefore, further research is necessary to define the best formulations of
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probiotics for in ovo injections to improve live performance and effectively provide the
chick with complete protection against antigens in the external environment. Similarly,
the combination of in ovo and in feed probiotic supplementation may prove effective in
maintaining chick performance and chick health throughout an entire grow-out. Once
these formulations are perfected, further studies should include more diverse challenges
with pathogenic bacteria species, such as a combination of coccidiosis and Clostridium
spp.
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Tables
Table 4.1

Effect of in ovo injected HVT vaccine (Control), L. animalis, B.
licheniformis, or their combination on hatch parameters
Control

L. animalis

B. licheniformis

Combination

P value

Hatch of Transfer
(%)

92.6

94.4

95.2

94.2

0.61

Average Chick
Wt (g)

46.0

45.4

45.1

45.0

0.39

Late Dead Eggs
(%)

5.2a

3.6ab

1.9b

3.6ab

0.04

Pipped Eggs (%)

2.2

1.2

1.4

1.4

0.89

Cracked Eggs
(%)

0.0

0.0

0.2

0.2

0.60

Contaminated
Eggs (%)

0.0

0.7

0.0

0.0

0.44

Culled Eggs (%)

0.0

0.0

0.0

0.0

.

SEM

1.4

0.4

0.6

0.8

0.1

0.6

0.1

Different superscripts (a - b) indicate significant differences in the means of treatments,
where differences are considered significant at P ≤ 0.05. N = 3, where each replicate in
the treatment was a GQF hatcher unit (~210 eggs/GQF; 630 total eggs/treatment).
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Table 4.2

Treatment main effects on hematological parameters over the first 28 days
of a 49 day grow-out of chicks in ovo injected with HVT vaccine (Control),
L. animalis, B. licheniformis, or their combination

Control

L. animalis

B. licheniformis

Combination

P
value

SEM

Total WBC
count
(thou/µL)

27656ab

31667a

27056ab

23233b

0.02

1640

H/L Ratio

0.324

0.367

0.417

0.406

0.17

0.03

Heterophils
(%)

15.86b

19.66ab

21.74a

22.32a

0.01

1.34

Lymphocytes
(%)

47.62

53.56

53.87

56.1

0.07

2.19

Eosinophils
(%)

5.03

5.25

5.37

6.25

0.08

0.33

Different superscripts (a - b) indicate significant differences in the means of treatments,
where differences are considered significant at P ≤ 0.05. N = 6, where each replicate in
the treatment was a pen in the grow-out facility (18 birds/pen; 216 total bird/treatment).
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Table 4.3
Phase

d 0-14

d 14-28

d 28-49

d 0-28

d 0-49

Effect of in ovo injected HVT vaccine (Control), L. animalis, B. licheniformis, or their combination on live performance
parameters over a 49 d grow-out
Parameter Measured

Control

L. animalis

B. licheniformis

Combination

P value

SEM

Live Wt. Gain (kg)

0.42

0.44

0.43

0.44

0.30

0.01

FCR (kg/kg)

1.21

1.21

1.21

1.21

0.99

0.01

Mortality (%)

0.93

0.46

0.46

0.93

0.87

0.55

Live Wt. Gain (kg)

1.20

1.21

1.22

1.2

0.48

0.01

FCR (kg/kg)

1.38

b

1.40

a

b

0.03

0.01

Mortality (%)

0.52

0.57

0

1.08

0.56

0.54

Live Wt. Gain (kg)

2.38

2.32

2.29

2.23

0.19

0.05

FCR (kg/kg)

1.77

1.83

1.79

1.88

0.08

0.03

Mortality (%)

4.30

4.17

5.36

2.98

0.74

1.51

Live Wt. Gain (kg)

1.62

1.65

1.65

1.65

0.28

0.01

FCR (kg/kg)

1.33

1.34

1.32

1.34

0.11

0.01

Mortality (%)

1.85

1.39

0.93

0.46

0.64

0.79

Live Wt. Gain (kg)

3.84

3.92

3.95

4.00

0.31

0.02

FCR (kg/kg)

1.60

1.61

1.59

1.58

0.25

0.05

Mortality (%)

3.24

3.70

4.63

4.02

0.48

1.33

1.37

1.39

ab

Different superscripts (a - b) indicate significant differences in the means of treatments, where differences are considered significant at
P ≤ 0.05. N = 12, where each replicate in the treatment was a pen in the grow-out facility (18 birds/pen; 216 total bird/treatment).
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Table 4.4

Treatment by day interaction for percentage (%) of chicks exhibiting red
lesions after a coccidiosis challenge according to score in the in ovo
injected HVT vaccination control, L. animalis, B. licheniformis, or
combination treatments on d 21 and 28 of a 49 day grow-out

Treatment

Day

Duodenum

Jejunum

Ileum

0

1

0

1

2

0

1

d 21

100

0

33

58

8

100

0

d 28

92

8

58

42

0

83

17

d 21

100

0

25

58

17

58

42

d 28

92

8

42

42

17

92

8

d 21

100

0

33

67

0

83

17

d 28

100

0

67

33

0

92

8

d 21

100

0

33

50

17

92

8

d 28

100

0

42

58

0

83

17

P value

0.58

0.58

0.84

0.57

0.68

0.11

0.11

SEM

4.2

4.2

14.3

14.7

7.9

10.7

10.7

HVT Control

L. animalis

B. licheniformis

Combination

Different superscripts indicate significant differences in the means of treatments, where
differences are considered significant at P ≤ 0.05. N = 12, where each replicate in the
treatment was a pen in the grow-out facility (18 birds/pen; 216 total bird/treatment).
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Table 4.5

Treatment by day interaction for percentage (%) of chicks exhibiting white
lesions after a coccidiosis challenge according to score in the in ovo
injected HVT vaccination control, L. animalis, B. licheniformis, or
combination treatments on d 21 and 28 of a 49 day grow-out

Treatment

Day

Duodenum

Jejunum

0

1

2

0

1

2

d 21

8

83

8

100

0

0

d 28

33

58

8

42

50

8

d 21

8

67

25

75

17

8

d 28

33

50

17

25

50

25

d 21

25

58

17

92

8

0

d 28

42

50

8

42

50

8

d 21

8

92

0

92

8

0

d 28

33

67

0

33

50

17

P value

0.98

0.88

0.93

0.97

0.91

0.92

SEM

12.5

12.0

8.6

11.4

11.3

8.2

HVT Control

L. animalis

B. licheniformis

Combination

Different superscripts indicate significant differences in the means of treatments, where
differences are considered significant at P ≤ 0.05. N = 12, where each replicate in the
treatment was a pen in the grow-out facility (18 birds/pen; 216 total bird/treatment).
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Figure 4.1

Treatment by day interaction for percent lymphocytes (%) over the first 28
days of a 49 day grow-out of chicks in ovo injected with HVT vaccine
(Control), L. animalis, B. licheniformis, or their combination

A treatment by day interaction was observed for percent lymphocytes. The HVT control
injection is represented by the gray shaded bar. The L. animalis injected probiotic
treatment is represented by the white shaded bar. The B. licheniformis injected probiotic
treatment is represented by the dotted bar. The L. animlais + B. licheniformis
combination injected probiotic treatment is represented by the hashed bar. Percent
lymphocytes (%) is on the y-axis, and day of grow-out (d 0, d 21, and d 28) is on the xaxis. The SEM and P value is located in the bottom right corner of the figure. Differences
were considered significant at P ≤ 0.05, error bars represent the SEM, and N = 12 (12
pens/treatment; one bird randomly sampled from each pen on each sampling day).
Significant differences are noted by alphabetical superscripts, where each change in a
letter represents a significant difference among treatments. The superscripts for this
figure include a - d.
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Figure 4.2

Trend from the in ovo injected HVT vaccine (Control), L. animalis, B.
licheniformis, or their combination on bursa weight relative to body weight
(%) of chicks over the 49 day grow-out

Treatment by day interaction for bursa of Fabricius weight relative to body weight is
represented on this figure. The HVT control injection is represented by the gray shaded
bar. The L. animalis injected probiotic treatment is represented by the white shaded bar.
The B. licheniformis injected probiotic treatment is represented by the dotted bar. The L.
animlais + B. licheniformis combination injected probiotic treatment is represented by the
hashed bar. Bursa weight relative to body weight (%) is on the y-axis, and day of growout (d 0, d 7, d 14, d 21, and d 28) is on the x-axis. The SEM and P value is located in the
bottom right corner of the figure. Differences were considered significant at P ≤ 0.05,
error bars represent the SEM, and N = 12 (12 pens/treatment; one bird randomly sampled
from each pen on each sampling day).
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Figure 4.3

Trend from the in ovo injected HVT vaccine (Control), L. animalis, B.
licheniformis, or their combination on gross bursa weight (g) of chicks over
the first 28 days of a 49 day grow-out

Treatment by day interaction for gross bursa weight is represented on this figure. The
HVT control injection is represented by the gray shaded bar. The L. animalis injected
probiotic treatment is represented by the white shaded bar. The B. licheniformis injected
probiotic treatment is represented by the dotted bar. The L. animlais + B. licheniformis
combination injected probiotic treatment is represented by the hashed bar. Gross bursa
weight (g) is on the y-axis, and day of grow-out (d 0, d 7, d 14, d 21, and d 28) is on the
x-axis. The SEM and P value is located in the bottom right corner of the figure.
Differences were considered significant at P ≤ 0.05, error bars represent the SEM, and N
= 12 (12 pens/treatment; one bird randomly sampled from each pen on each sampling
day).
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Trend from the in ovo injected HVT vaccine (Control), L. animalis, B.
licheniformis, or their combination on bursa follicle area (µm2) of chicks
over the first 28 days of a 49 day grow-out

Treatment by day interaction for bursa of Fabricius follicle area is represented on this
figure. The HVT control injection is represented by the gray shaded bar. The L. animalis
injected probiotic treatment is represented by the white shaded bar. The B. licheniformis
injected probiotic treatment is represented by the dotted bar. The L. animlais + B.
licheniformis combination injected probiotic treatment is represented by the hashed bar.
Bursa follicle area (µm2) is on the y-axis, and day of grow-out (d 0, d 21, and d 28) is on
the x-axis. The SEM and P value is located in the bottom right corner of the figure.
Differences were considered significant at P ≤ 0.05, error bars represent the SEM, and N
= 12 (12 pens/treatment; one bird randomly sampled from each pen on each sampling
day).
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Figure 4.5

Trend from the in ovo injected HVT vaccine (Control), L. animalis, B.
licheniformis, or their combination on spleen weight relative to body
weight (%) of chicks over the 49 day grow-out

Treatment by day interaction for spleen weight relative to body weight is represented on
this figure. The HVT control injection is represented by the gray shaded bar. The L.
animalis injected probiotic treatment is represented by the white shaded bar. The B.
licheniformis injected probiotic treatment is represented by the dotted bar. The L.
animlais + B. licheniformis combination injected probiotic treatment is represented by the
hashed bar. Spleen weight relative to body weight (%) is on the y-axis, and day of growout (d 0, d 7, d 14, d 21, and d 28) is on the x-axis. The SEM and P value is located in the
bottom right corner of the figure. Differences were considered significant at P ≤ 0.05,
error bars represent the SEM, and N = 12 (12 pens/treatment; one bird randomly sampled
from each pen on each sampling day).
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Figure 4.6

Trend from the in ovo injected HVT vaccine (Control), L. animalis, B.
licheniformis, or their combination on gross spleen weight (g) of chicks
over the 49 day grow-out

Treatment by day interaction for gross spleen weight is represented on this figure. The
HVT control injection is represented by the gray shaded bar. The L. animalis injected
probiotic treatment is represented by the white shaded bar. The B. licheniformis injected
probiotic treatment is represented by the dotted bar. The L. animlais + B. licheniformis
combination injected probiotic treatment is represented by the hashed bar. Gross spleen
weight (g) is on the y-axis, and day of grow-out (d 0, d 7, d 14, d 21, and d 28) is on the
x-axis. The SEM and P value is located in the bottom right corner of the figure.
Differences were considered significant at P ≤ 0.05, error bars represent the SEM, and N
= 12 (12 pens/treatment; one bird randomly sampled from each pen on each sampling
day).
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Figure 4.7

Treatment by day interaction for IL-6 quantification (ng) over the first 28
days of a 49 day grow-out of chicks in ovo injected with HVT vaccine
(Control), L. animalis, B. licheniformis, or their combination

A treatment by day interaction was observed for IL-6. The HVT control injection is
represented by the gray shaded bar. The L. animalis injected probiotic treatment is
represented by the white shaded bar. The B. licheniformis injected probiotic treatment is
represented by the dotted bar. The L. animlais + B. licheniformis combination injected
probiotic treatment is represented by the hashed bar. Quantified IL-6 (ng/mL) is on the yaxis, and day of grow-out (d 0, d 21, and d 28) is on the x-axis. The SEM and P value is
located in the bottom right corner of the figure. Differences were considered significant at
P ≤ 0.05, error bars represent the SEM, and N = 12 (12 pens/treatment; one bird
randomly sampled from each pen on each sampling day). Significant differences are
noted by alphabetical superscripts, where each change in a letter represents a significant
difference among treatments. The superscripts for this figure include a - b.
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Figure 4.8

Treatment by day interaction for IL-10 quantification (ng) over the first 28
days of a 49 day grow-out of chicks in ovo injected with HVT vaccine
(Control), L. animalis, B. licheniformis, or their combination

A treatment by day interaction was observed for IL-10. The HVT control injection is
represented by the gray shaded bar. The L. animalis injected probiotic treatment is
represented by the white shaded bar. The B. licheniformis injected probiotic treatment is
represented by the dotted bar. The L. animlais + B. licheniformis combination injected
probiotic treatment is represented by the hashed bar. Quantified IL-10 (ng/mL) is on the
y-axis, and day of grow-out (d 0, d 21, and d 28) is on the x-axis. The SEM and P value is
located in the bottom right corner of the figure. Differences were considered significant at
P ≤ 0.05, error bars represent the SEM, and N = 12 (12 pens/treatment; one bird
randomly sampled from each pen on each sampling day). Significant differences are
noted by alphabetical superscripts, where each change in a letter represents a significant
difference among treatments. The superscripts for this figure include a - b.
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Figure 4.9

Treatment by day interaction for IL-12-p40 quantification (ng) over the
first 28 days of a 49 day grow-out of chicks in ovo injected with HVT
vaccine (Control), L. animalis, B. licheniformis, or their combination

A treatment by day interaction was observed for IL-12-p40. The HVT control injection is
represented by the gray shaded bar. The L. animalis injected probiotic treatment is
represented by the white shaded bar. The B. licheniformis injected probiotic treatment is
represented by the dotted bar. The L. animlais + B. licheniformis combination injected
probiotic treatment is represented by the hashed bar. Quantified IL-12-p40 (ng/mL) is on
the y-axis, and day of grow-out (d 0, d 21, and d 28) is on the x-axis. The SEM and P
value is located in the bottom right corner of the figure. Differences were considered
significant at P ≤ 0.05, error bars represent the SEM, and N = 12 (12 pens/treatment; one
bird randomly sampled from each pen on each sampling day). Significant differences are
noted by alphabetical superscripts, where each change in a letter represents a significant
difference among treatments. The superscripts for this figure include a - b.
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Figure 4.10

Treatment by day interaction for IL-16 quantification (ng) over the first 28
days of a 49 day grow-out of chicks in ovo injected with HVT vaccine
(Control), L. animalis, B. licheniformis, or their combination

A treatment by day interaction was observed for IL-16. The HVT control injection is
represented by the gray shaded bar. The L. animalis injected probiotic treatment is
represented by the white shaded bar. The B. licheniformis injected probiotic treatment is
represented by the dotted bar. The L. animlais + B. licheniformis combination injected
probiotic treatment is represented by the hashed bar. Quantified IL-16 (ng/mL) is on the
y-axis, and day of grow-out (d 0, d 21, and d 28) is on the x-axis. The SEM and P value is
located in the bottom right corner of the figure. Differences were considered significant at
P ≤ 0.05, error bars represent the SEM, and N = 12 (12 pens/treatment; one bird
randomly sampled from each pen on each sampling day). Significant differences are
noted by alphabetical superscripts, where each change in a letter represents a significant
difference among treatments. The superscripts for this figure include a - c.
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Figure 4.11

Treatment by day interaction for IL-21 quantification (ng) over the first 28
days of a 49 day grow-out of chicks in ovo injected with HVT vaccine
(Control), L. animalis, B. licheniformis, or their combination

A treatment by day interaction was observed for IL-21. The HVT control injection is
represented by the gray shaded bar. The L. animalis injected probiotic treatment is
represented by the white shaded bar. The B. licheniformis injected probiotic treatment is
represented by the dotted bar. The L. animlais + B. licheniformis combination injected
probiotic treatment is represented by the hashed bar. Quantified IL-21 (ng/mL) is on the
y-axis, and day of grow-out (d 0, d 21, and d 28) is on the x-axis. The SEM and P value is
located in the bottom right corner of the figure. Differences were considered significant at
P ≤ 0.05, error bars represent the SEM, and N = 12 (12 pens/treatment; one bird
randomly sampled from each pen on each sampling day). Significant differences are
noted by alphabetical superscripts, where each change in a letter represents a significant
difference among treatments. The superscripts for this figure include a - b.
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Figure 4.12

Treatment by day interaction for ileum weight relative to body weight (%)
over a 49 day grow-out of chicks in ovo injected with HVT vaccine
(Control), L. animalis, B. licheniformis, or their combination

A treatment by day interaction was observed for ileum weight relative to body weight.
The HVT control injection is represented by the gray shaded bar. The L. animalis injected
probiotic treatment is represented by the white shaded bar. The B. licheniformis injected
probiotic treatment is represented by the dotted bar. The L. animlais + B. licheniformis
combination injected probiotic treatment is represented by the hashed bar. Ileum weight
relative to body weight (%) is on the y-axis, and day of grow-out (d 0, d 7, d 14, d 21, and
d 28) is on the x-axis. The SEM and P value is located in the bottom right corner of the
figure. Differences were considered significant at P ≤ 0.05, error bars represent the SEM,
and N = 12 (12 pens/treatment; one bird randomly sampled from each pen on each
sampling day). Significant differences are noted by alphabetical superscripts, where each
change in a letter represents a significant difference among treatments. The superscripts
for this figure include a - g.
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Figure 4.13

Treatment by day interaction for gross ileum weight over a 49 day growout of chicks in ovo injected with HVT vaccine (Control), L. animalis, B.
licheniformis, or their combination

A treatment by day interaction was observed for gross ileum weight. The HVT control
injection is represented by the gray shaded bar. The L. animalis injected probiotic
treatment is represented by the white shaded bar. The B. licheniformis injected probiotic
treatment is represented by the dotted bar. The L. animlais + B. licheniformis
combination injected probiotic treatment is represented by the hashed bar. Gross ileum
weight (g) is on the y-axis, and day of grow-out (d 0, d 7, d 14, d 21, and d 28) is on the
x-axis. The SEM and P value is located in the bottom right corner of the figure.
Differences were considered significant at P ≤ 0.05, error bars represent the SEM, and N
= 12 (12 pens/treatment; one bird randomly sampled from each pen on each sampling
day). Significant differences are noted by alphabetical superscripts, where each change in
a letter represents a significant difference among treatments. The superscripts for this
figure include a - i.
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Figure 4.14

Trend from the in ovo injected HVT vaccine (Control), L. animalis, B.
licheniformis, or their combination on ceca weight relative to body weight
(%) over a 49 day grow-out

Treatment by day interaction for ceca weight relative to body weight is represented on
this figure. The HVT control injection is represented by the gray shaded bar. The L.
animalis injected probiotic treatment is represented by the white shaded bar. The B.
licheniformis injected probiotic treatment is represented by the dotted bar. The L.
animlais + B. licheniformis combination injected probiotic treatment is represented by the
hashed bar. Ceca weight relative to body weight (%) is on the y-axis, and day of grow-out
(d 0, d 7, d 14, d 21, and d 28) is on the x-axis. The SEM and P value is located in the
bottom right corner of the figure. Differences were considered significant at P ≤ 0.05,
error bars represent the SEM, and N = 12 (12 pens/treatment; one bird randomly sampled
from each pen on each sampling day).
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Figure 4.15

Trend from the in ovo injected HVT vaccine (Control), L. animalis, B.
licheniformis, or their combination on gross ceca weight (g) over a 49 day
grow-out

Treatment by day interaction for gross ceca weight is represented on this figure. The
HVT control injection is represented by the gray shaded bar. The L. animalis injected
probiotic treatment is represented by the white shaded bar. The B. licheniformis injected
probiotic treatment is represented by the dotted bar. The L. animlais + B. licheniformis
combination injected probiotic treatment is represented by the hashed bar. Gross ceca
weight (g) is on the y-axis, and day of grow-out (d 0, d 7, d 14, d 21, and d 28) is on the
x-axis. The SEM and P value is located in the bottom right corner of the figure.
Differences were considered significant at P ≤ 0.05, error bars represent the SEM, and N
= 12 (12 pens/treatment; one bird randomly sampled from each pen on each sampling
day).
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CONCLUSION
Although in ovo technology has been used in commercial poultry production for
over 30 years, its primary use in the industry is for vaccine administration into a fertilized
egg. The in ovo injection of probiotic formulations is proposed as a viable antibiotic
alternative due to the beneficial impacts that probiotics exhibit when supplemented in a
diet. Benefits attributed to probiotic supplementation in mammalian models range from
pathogen reduction in the gastrointestinal tract to immunomodulation within a host at the
site of an infection. These attributes are translated to avian models, where the dietary
inclusion of probiotics decreases FCR and increases body weight gain in broiler chickens.
Through the in ovo injection of a combination of probiotic species, the chick may
be able to promote the early colonization of a more diverse microflora prior to hatch. This
may be advantageous for the chick, as it potentially provides the chick with a more
developed barrier of protection in the gut against pathogens in the hatchery and grow-out
facility. Concurrently, previous research has noted that the components of the
gastrointestinal microbiome can play a pivotal role in host health. Disruptions in the gut
microbiome have been linked to many infectious diseases, metabolic syndromes, mental
health, and autoimmune disorders in humans.
Therefore, through the supplementation of probiotic combinations prior to hatch,
the current study attempted to analyze hatch performance, live performance, and
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immune-physiological alterations among chicks. In the first study, the in ovo injection of
L. animalis + E. faecium observed potential benefits for the injection of only L. animalis
on hatch performance due to a decrease in percent pipped eggs. This study was followed
by the in ovo injection of L. animalis + B. licheniformis, where the injection of only B.
licheniformis decreased percent late dead eggs when compared to the HVT control. In
both trials, the in ovo supplementation of probiotic combinations did not cause any
decrease in hatchability when compared to the HVT control. Moreover, these two studies
confirmed that the in ovo injection of two probiotics belonging to two different genera
with differing modes of action would not negatively impact hatch performance.
Both studies exhibited the continued influence that this in ovo supplementation of
probiotics has on gastrointestinal tissue development. In both studies, the individual
probiotics and their combinations were capable of altering gastrointestinal tissue weight
throughout their respective grow-outs. This may have translated into an increase in FCR
for both studies after the first week of grow-out. However, histological analysis of the
gastrointestinal tissues is necessary to gain further understanding for these changes in gut
tissue weights. Similarly, a microbiome analysis of the subsequent sections of the
gastrointestinal tract may provide insight into how bacterial populations are altered by
these in ovo probiotic supplementations. In addition, a microbiome analysis would
exhibit any changes in bacterial populations occurring when there are increases in FCR
during the grow-out.
The in ovo injection of L. animalis + B. licheniformis also exhibited
immunological modulation throughout the grow-out and during a coccidiosis challenge.
The in ovo supplementation of these probiotic cultures individually and in combinations
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altered bursa physiology, circulating white blood cell profiles, and cytokine quantities
over the first 28 days of life. This initial supplementation also exhibited potential for
providing the chick with an advantage against a coccidiosis challenge during grow-out
(especially for those supplemented with B. licheniformis). However, further studies are
necessary to understand these immunological interactions. Also, immunoglobulin
quantification may be an additional parameter analyzed for immunological stimulation in
the future.
Moreover, the in ovo injection of probiotics is continually proven to be a viable
practice for commercial poultry production. However, the probiotic formulation that is
injected into the fertile egg may need perfected before any live performance benefits are
observed. It may also be necessary to supplement the probiotics both in ovo and in feed to
yield benefits. Probiotic bacteria injected in ovo may be lost later in the grow-out, and
continued supplementation in the feed may allow for the bird to maintain that probiotic in
its gut over the course of a 49 day grow-out. Additionally, an analysis of the cecal
microbiome may provide further insight into live performance and immunological
modulation observed in the present study. In conclusion, further research is necessary to
perfect in ovo probiotic supplementation. However, the methodology has potential to
improve chick health and may become a viable practice in the industry in the future to
reduce pathogen presence in the gut and improve broiler performance.
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